var docs;if (!docs) docs =[]; docs["44"]={"4400":"<p><b>Title</b> Regadenoson / Dipyridamole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dipyridamole may enhance the adverse/toxic effect of Regadenoson. Specifically, adenosine mediated effects may be enhanced. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Dipyridamole should be avoided for at least 48 hours prior to the administration of regadenoson.</p> \n<p><b>Discussion</b> Dipyridamole inhibits the activity of adenosine deaminase and phosphodiesterase. This enzyme inhibition results in an accumulation of adenosine, adenine nucleotides, and cyclic AMP and leads to inhibition of platelet aggregation and vasodilation. Dipyridamole may also stimulate release of prostacyclin or PGD2 resulting in coronary vasodilation. Concomitant administration of dipyridamole and regadenoson may result in increased blood levels and pharmacologic effects of adenosine. As regadenoson is an adenosine receptor (specifically A<sub>2A</sub>) agonist, the adenosine-potentiating effects of dipyridamole may enhance the effects of regadenoson. The manufacturer of regadenoson recommends withholding dipyridamole for at least 48 hours prior to the administration of regadenoson.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lexiscan (regadenoson). Deerfield, Il: Astellas Pharma US, Inc., 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4401":"<p><b>Title</b> Fexofenadine / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Fexofenadine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid co-administration of fexofenadine together with aluminum and magnesium containing antacids. No specific recommendations concerning the time required between their administration are provided. It appears prudent to separate administration of each agent by as much time as possible to decrease the risk of a significant interaction.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Diomagnite, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate<br><b>Exceptions</b> Calcium Carbonate, Magaldrate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Fexofenadine prescribing information states that administration of an aluminum and magnesium containing antacid within 15 minutes of fexofenadine resulted in a decrease of both fexofenadine AUC and Cmax by 41% and 43%, respectively.<sup>1</sup> The suspected mechanism of this interaction is an antacid-mediated decrease in fexofenadine absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Allegra (fexofenadine). Bridgewater, NJ: Sanofi-Aventis, July 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4402":"<p><b>Title</b> DAPTOmycin / HMG-CoA Reductase Inhibitors (Statins)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> HMG-CoA Reductase Inhibitors (Statins) may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to initiating daptomycin in order to decrease the risk of skeletal muscle toxicity. If daptomycin is used together with an HMG-CoA reductase inhibitor, it is recommended that CPK concentrations are measured frequently (at least weekly).</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> In a small controlled clinical trial described in the daptomycin prescribing information, there was no difference in adverse events between healthy volunteers receiving daptomycin (4mg/kg IV daily) together with simvastatin 40mg/day for 14 days (n=10) and those receiving daptomycin plus placebo (n=10).<sup>1</sup> Conversely, in a phase III study of patients with bacteremia or endocarditis, 5/22 (22.7%) patients receiving concurrent daptomycin and an HMG-CoA reductase inhibitor had CPK concentrations greater than 500 U/L.<sup>1</sup> Overall, according to the daptomycin prescribing information, 2.8-6.7% of patients in phase III trials of daptomycin (at 4-6 mg/kg) experienced CPK elevations (vs. less than 2% in comparators).<sup>1</sup> Several case reports describe skeletal muscle toxicities possibly related to daptomycin.<sup>2,3,4,5,6</sup> Of these cases, none involved concurrent HMG-CoA reductase inhibitors, though one occurred in a patient who had their simvastatin therapy stopped prior to daptomycin treatment (according to labeling).<sup>2</sup> In that case, signs and symptoms of myopathy were first present on day 9 of daptomycin therapy, making any association with prior simvastatin therapy unclear.<br><br>The mechanism of any possible interaction between daptomycin and the HMG-CoA reductase inhibitors is uncertain, but may be related to the potential of each agent to cause skeletal muscle toxicity (e.g., myalgia, myopathy, rhabdomyolysis).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cubicin (daptomycin). Lexington, MA: Cubist Pharmaceuticals, Inc., October 2007.</p>\n<p>2. Echevarria K, Datta P, Cadena J, et al, “Severe Myopathy and Possible Hepatotoxicity Related to Daptomycin,” <i>J Antimicrob Chemother</i>, 2005, 55:599-600. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15743894\">[PubMed 15743894]</a></p>\n<p>3. Kazory A, Dibadj K, Weiner ID, “Rhabdomyolysis and Acute Renal Failure in a Patient Treated with Daptomycin,” <i>J Antimicrob Chemother</i>, 2006, 57:578-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16410267\">[PubMed 16410267]</a></p>\n<p>4. Papadopoulos S, Ball AM, Liewer SE, et al, “Rhabdomyolysis During Therapy with Daptomycin,” <i>Clin Infect Dis</i>, 2006, 42:e108-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16705566\">[PubMed 16705566]</a></p>\n<p>5. Patel SJ, Samo TC, Suki WN, “Early-Onset Rhabdomyolysis Related to Daptomycin Use,” <i>Int J Antimicrob Agents</i>, 2007, 30:472-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17804204\">[PubMed 17804204]</a></p>\n<p>6. Veligandla SR, Louie KR, Malesker MA, et al, “Muscle Pain Associated with Daptomycin,” <i>Ann Pharmacother</i>, 2004, 38:1860-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15367725\">[PubMed 15367725]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4403":"<p><b>Title</b> Rifabutin / Nevirapine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Nevirapine. Nevirapine may decrease the serum concentration of Rifabutin. Nevirapine may increase the serum concentration of Rifabutin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to both rifabutin and nevirapine closely as both drugs have the potential to alter the pharmacokinetics of one another. Monitor plasma concentrations to aid clinical decision making when possible.</p> \n<p><b>Discussion</b> According to data presented in the nevirapine prescribing information, rifabutin (150mg or 300mg daily) AUC and maximum concentration (Cmax) increased by an average of 17% and 28%, respectively, during combination with nevirapine (200mg daily x 14 days, then 200mg twice daily x 14 days); however, rifabutin minimum concentration (Cmin) was not significantly altered.<sup>1</sup> The AUC, Cmax, and Cmin of the rifabutin metabolite 25-O-desacetyl-rifabutin were all increased (by means of 24%, 29%, and 22%, respectively) with concurrent nevirapine. Considering that both nevirapine and rifabutin are largely considered inducers of drug metabolism, the observed increase in rifabutin AUC and Cmax (though of only a moderate magnitude) is somewhat unexpected; although, according to nevirapine prescribing information, nevirapine is capable of acting as a competitive inhibitor of CYP3A4 (enzyme primarily responsible for rifabutin metabolism) as well. The observed increase in concentrations of the main rifabutin metabolite may be reflective of increased metabolite formation (i.e., increased conversion of parent to metabolite), despite evidence of increased parent exposure, and/or decreased metabolite elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Viramune (nevirapine). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc, June 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4404":"<p><b>Title</b> Nevirapine / RifAMPin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b> (Tablet, extended release): Extended-release nevirapine should not be used with rifampin, whereas immediate-release nevirapine may be used under some circumstances.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Nevirapine. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> According to nevirapine prescribing information, concurrent use with rifampin should be avoided due to risk of decreased nevirapine effectiveness. Consequently, alternatives such as rifabutin instead of rifampin (because of less severe interactions due to less potent enzyme induction) and/or using efavirenz rather than nevirapine, when possible and clinically justified, are preferred. When nevirapine and rifampin must be used in combination, current guidelines for adults and adolescents call for the use of immediate-release nevirapine (avoid extended-release nevirapine) at a dose of 200 mg twice daily with no lead-in period. Monitor nevirapine response closely.</p> \n<p><b>Discussion</b> Nevirapine AUC, minimum plasma concentration (Cmin), and maximum plasma concentration (Cmax) have displayed mean decreases of 31-46%, 21-53%, and 36-42%, respectively, with concurrent rifampin according to several studies of 10-74 patients.<sup>1,2,3,4</sup> According to data in the nevirapine prescribing information, nevirapine AUC and Cmax were decreased by more than 50% when combined with rifampin (600mg daily).<sup>5</sup> This combination has also been associated with more subtherapeutic nevirapine concentrations in many reports (and clinical virologic failure in one<sup>?#</sup>);<sup>2,3,4,6</sup> although, several others have described equal clinical effectiveness despite the lower nevirapine concentrations,<sup>1,7,8</sup> extending out to 24 month<sup>7</sup> and 60 month<sup>8</sup> follow-ups.<br><br>In spite of one study concluding that an increase of the nevirapine dose from 200mg twice daily to 300mg twice daily may avoid the subtherapeutic nevirapine concentrations observed in several studies,<sup>3</sup> current HIV guidelines recommend using standard nevirapine dosing when used together with rifampin.<sup>9</sup> This recommendation appears to be based on reports of sustained effectiveness at standard nevirapine doses<sup>1,7,8</sup> and concerns regarding a possibly increased risk of nevirapine hypersensitivity with the higher dose.<sup>10</sup><br><br>The mechanism of this interaction appears to be rifampin-mediated induction of nevirapine metabolism. Evidence that rifampin-containing regimens were associated with a significant decrease in the ratio of nevirapine AUC to 12-hydroxy-nevirapine AUC<sup>4</sup> supports this theory.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ribera E, Pou L, Lopez RM, et al, “Pharmacokinetic Interaction between Nevirapine and Rifampicin in Hiv-Infected Patients with Tuberculosis,” <i>J Acquir Immune Defic Syndr</i>, 2001, 28:450-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11744833\">[PubMed 11744833]</a></p>\n<p>2. Autar RS, Wit FW, Sankote J, et al, “Nevirapine Plasma Concentrations and Concomitant Use of Rifampin in Patients Coinfected with Hiv-1 and Tuberculosis,” <i>Antivir Ther</i>, 2005, 10:937-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16430199\">[PubMed 16430199]</a></p>\n<p>3. Ramachandran G, Hemanthkumar AK, Rajasekaran S, et al, “Increasing Nevirapine Dose Can Overcome Reduced Bioavailability Due to Rifampicin Coadministration,” <i>J Acquir Immune Defic Syndr</i>, 2006, 42:36-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16639340\">[PubMed 16639340]</a></p>\n<p>4. Cohen K, van Cutsem G, Boulle A, et al, “Effect of Rifampicin-Based Antitubercular Therapy on Nevirapine Plasma Concentrations in South African Adults with Hiv-Associated Tuberculosis,” <i>J Antimicrob Chemother</i>, 2008, 61:389-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18096560\">[PubMed 18096560]</a></p>\n<p>5. Prescribing information. Viramune (nevirapine). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc, June 2007.</p>\n<p>6. van Oosterhout JJ, Kumwenda JJ, Beadsworth M, et al, “Nevirapine-Based Antiretroviral Therapy Started Early in the Course of Tuberculosis Treatment in Adult Malawians,” <i>Antivir Ther</i>, 2007, 12:515-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17668560\">[PubMed 17668560]</a></p>\n<p>7. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al, “Plasma Nevirapine Levels and 24-Week Efficacy in Hiv-Infected Patients Receiving Nevirapine-Based Highly Active Antiretroviral Therapy with or without Rifampicin,” <i>Clin Infect Dis</i>, 2006, 43:253-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16779754\">[PubMed 16779754]</a></p>\n<p>8. Manosuthi W, Ruxrungtham K, Likanonsakul S, et al, “Nevirapine Levels after Discontinuation of Rifampicin Therapy and 60-Week Efficacy of Nevirapine-Based Antiretroviral Therapy in Hiv-Infected Patients with Tuberculosis,” <i>Clin Infect Dis</i>, 2007, 44:141-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17143831\">[PubMed 17143831]</a></p>\n<p>9. U.S. Department of Health and Human Services, “Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents ,” May 2013, Accessed online at http://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0 on 5/15/13.</p>\n<p>10. Avihingsanon A, Manosuthi W, Kantipong P, et al, “Pharmacokinetics and 12 Weeks Efficacy of Nevirapine, 400mg vs. 600mg per Day in HIV-Infected Patients with Active TB Receiving Rifampicin: A Multicenter Study,” Paper presented at 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4405":"<p><b>Title</b> Indinavir / Didanosine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is only expected with buffered didanosine preparations.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Didanosine may decrease the serum concentration of Indinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Indinavir should be administered on an empty stomach at least 1 hour apart from administration of buffer-containing formulations of didanosine.</p> \n<p><b>Discussion</b> According to indinavir prescribing information, indinavir administration should be at least 1 hour apart from administration of buffer-containing formulations of didanosine.<sup>1</sup> The reason for this precaution is likely to minimize the risk of a decrease in indinavir absorption caused by a buffer-mediated increase in pH. Concurrent use of H2-receptor antagonists with indinavir has been associated with a minimal-moderate decrease in indinavir Cmin.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Crixivan (indinavir). Whitehouse Station, NJ: Merck &amp; Co., Inc., September 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4407":"<p><b>Title</b> Factor IX Complex (Human) [(Factors II, IX, X)] / Aminocaproic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Aminocaproic Acid may enhance the adverse/toxic effect of Factor IX Complex (Human) [(Factors II, IX, X)]. Specifically, use of this combination may increase the risk of thrombosis. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of Aminocaproic Acid and Factor IX Complex concentrates.</p> \n<p><b>Discussion</b> Aminocaproic acid US prescribing information states that it should not be administered with factor IX complex concentrates due to a potential increase in the risk of thrombosis.<sup>1</sup> While several published reports describe the use of factor IX products and aminocaproic acid in combination without clear evidence of an increase in thrombotic events,<sup>2,3,4</sup> a published case report describes a 15-year-old patient with severe bleeding who experienced acute myocardial infarction when receiving an factor IX (non-activated) concentrate and aminocaproic acid to control severe bleeding.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Amicar (aminocaproic acid) [prescribing information]. Newport, KY: Anodyne Pharmaceuticals Inc; August 2008.</p>\n<p>2. Djulbegovic B, Hannan MM, Bergman GE. Concomitant treatment with factor IX concentrates and antifibrinolytics in hemophilia B. <i>Acta Haematol</i>. 1995;94 Suppl 1:43-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7571994\">[PubMed 7571994]</a></p>\n<p>3. Corrigan JJ Jr. Oral bleeding in hemophilia: treatment with epsilon aminocaproic acid and replacement therapy. <i>J Pediatr</i>. 1972;80(1):124-128. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4536942\">[PubMed 4536942]</a></p>\n<p>4. Walsh PN, Rizza CR, Matthews JM, et al. Epsilon-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. <i>Br J Haematol</i>. 1971;20(5):463-475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4931484\">[PubMed 4931484]</a></p>\n<p>5. Agrawal BL, Zelkowitz L, Hletko P. Acute myocardial infarction in a young hemophiliac patient during therapy with Factor IX concentrate and epsilon aminocaproic acid. <i>J Pediatr</i>. 1981;98(6):931-933. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7229796\">[PubMed 7229796]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4410":"<p><b>Title</b> Bevacizumab / SUNItinib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> SUNItinib may enhance the adverse/toxic effect of Bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of SUNItinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The combined use of bevacizumab with sunitinib is not recommended. If these agents are used together, monitor patients closely for both evidence of microangiopathic hemolytic anemia (MAHA) and development of hypertension (i.e., check blood pressure at least every 2-3 weeks). If hypertension develops, use blood pressure-lowering treatments as clinically appropriate. If severe hypertension develops, temporarily suspend sunitinib and/or bevacizumab until blood pressure is better controlled.</p> \n<p><b>Discussion</b> Of 12 patients with solid tumors who were receiving bevacizumab (10 mg/kg IV every 2 weeks) with sunitinib (50 mg/day orally), more than 40% (5/12) displayed laboratory evidence consistent with microangiopathic hemolytic anemia (MAHA).<sup>1,2</sup> Two of these cases were regarded as serious and included other signs and symptoms, including hypertension, serum creatinine elevations, proteinuria, and thrombocytopenia. This was the cohort receiving the highest of 3 sunitinib doses in the larger study of 25 patients (other doses included 25mg and 37.5mg daily). Adverse events including MAHA (in 2/7 patients in a phase 2 study), myelosuppression, fatigue, and various gastrointestinal events have been reported in other trials of bevacizumab plus sunitinib, which reportedly have all been stopped.<sup>1</sup> The specific mechanism(s) of this interaction is uncertain.<br><br>An additional concern regarding the concurrent use of these agents is the risk for hypertension. Of 25 patients with renal cell carcinoma who were treated with sunitinib (25 mg, 37.5 mg, or 50 mg daily for days 1-28 of 42-day cycle) and bevacizumab (10 mg/kg IV on days 0, 14, and 28 of cycle), 23 (92%) developed hypertension, including 15 (60%) with grade 3 or 4 hypertension.<sup>3</sup> Higher dose sunitinib appeared to be associated more severe hypertension, with 10 of the 12 patients (83%) receiving sunitinib 50 mg experiencing grade 3 or 4 hypertension (including all 3 of the patients with grade 4 hypertension), versus only 5 of the 13 patients (38%) receiving lower sunitinib doses.<br><br>Both sunitinib and bevacizumab have been independently associated with hypertension. According to sunitinib prescribing information and the results of a systematic review and meta-analysis, 22-30% of sunitinib-treated patients developed hypertension, including 7-10% who developed higher-grade hypertension.<sup>4,5</sup> According to bevacizumab prescribing information, 5-18% of treated patients experienced grade 3 or 4 hypertension (mostly dose-dependent).<sup>6</sup><br><br>The specific mechanism for the hypertension-inducing effects of these agents (both independently and in combination) is uncertain, though inhibition of VEGF (vascular endothelial growth factor) signaling in the glomerulus by anti-VEGF treatments such as sunitinib (multitargeted kinase inhibitor, which inhibits several VEGF receptors) and bevacizumab (monoclonal antibody against VEGF) has been proposed as a possible explanation.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dear Healthcare Provider Letter. “IMPORTANT DRUG WARNING SUBJECT: Microangiopathic Hemolytic Anemia (MAHA) in Patients treated with Avastin (bevacizumab) and sunitinib malate,” Genentech, Inc., July 2008.</p>\n<p>2. Feldman DR, Ginsberg MB, Flombaum C, et al, “Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma,” <i>J Clin Oncol</i>, 2008, 26 (suppl): abstract 5100.</p>\n<p>3. Feldman DR, Baum MS, Ginsberg MS, et al, “Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma,” <i>J Clin Oncol</i>, 2009, 27:1432-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19224847\">[PubMed 19224847]</a></p>\n<p>4. Zhu X, Stergiopoulos K, Wu S, “Risk of Hypertension and Renal Dysfunction with an Angiogenesis Inhibitor Sunitinib: Systematic Review and Meta-Analysis,” <i>Acta Oncol</i>, 2009, 48(1):9-17. [PMID: 18752081]</p>\n<p>5. Prescribing information. Sutent (sunitinib). New York, NY: Pfizer Inc, 7/2009.</p>\n<p>6. Prescribing information. Avastin (bevacizumab). South San Francisco, CA: Genetech, Inc., May 2009.</p>\n<p>7. Patel TV, Morgan JA, Demetri GD, et al, “A Preeclampsia-Like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib,” <i>J Natl Cancer Inst</i>, 2008, 100(4):282-4. [PMID: 18270341]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4411":"<p><b>Title</b> Trastuzumab / PACLitaxel (Conventional)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trastuzumab may decrease the serum concentration of PACLitaxel (Conventional). PACLitaxel (Conventional) may increase the serum concentration of Trastuzumab. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for adverse effects and response to therapy, as these agents may alter concentrations of one another when used in combination.</p> \n<p><b>Discussion</b> According to trastuzumab prescribing information, average trastuzumab concentrations were 1.5-fold higher when given with paclitaxel than in combination with an anthracycline and cyclophosphamide.<sup>1</sup> This potential interaction was not, however, apparent in pooled pharmacokinetic data from patients in early-phase clinical trials of trastuzumab<sup>2</sup> or in a phase II study of 32 patients with HER2-overexpressing breast cancer,<sup>3</sup> as both of these studies reported no evidence of a pharmacokinetic interaction between trastuzumab and paclitaxel (though neither was designed specifically to examine the presence of such an interaction).<sup>2,3</sup> The mechanism by which paclitaxel would increase trastuzumab concentrations is not known.<br><br>Concurrent trastuzumab was associated with an approximate 25% reduction in maximum concentrations of both paclitaxel and its 6-OH metabolite in a crossover pharmacokinetic study of 10 patients with advanced breast cancer.<sup>4</sup> Paclitaxel AUC was also nonsignificantly lower (by approximately 9%) with trastuzumab, but paclitaxel clearance appeared unchanged by trastuzumab, suggesting a likely absorption-mediated interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Herceptin (trastuzumab). South San Francisco, CA: Genentech, Inc., May 2008.</p>\n<p>2. Bruno R, Washington CB, Lu JF, et al, “Population Pharmacokinetics of Trastuzumab in Patients with HER2+ Metastatic Breast Cancer,” <i>Cancer Chemother Pharmacol</i>, 2005, 56:361-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15868146\">[PubMed 15868146]</a> </p>\n<p>3. Leyland-Jones B, Gelmon K, Ayoub JP, et al, “Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination with Paclitaxel,” <i>J Clin Oncol</i>, 2003, 21:3965-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14507946\">[PubMed 14507946]</a> </p>\n<p>4. Furtlehner A, Schueller J, Jarisch I, et al, “Disposition of Paclitaxel (Taxol) and Its Metabolites in Patients with Advanced Breast Cancer (ABC) When Combined with Trastuzumab (Hercpetin),” <i>Eur J Drug Metab Pharmacokinet</i>, 2005, 30:145-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16250250\">[PubMed 16250250]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4412":"<p><b>Title</b> Immunosuppressants / Trastuzumab</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trastuzumab may enhance the neutropenic effect of Immunosuppressants. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for neutropenia and/or anemia when trastuzumab is used in combination with immunosuppressant agents (particularly with myelosuppressive chemotherapy agents).</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, AzaTHIOprine, Basiliximab, Beclomethasone (Oral Inhalation), Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Betamethasone (Systemic), Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Budesonide (Systemic), Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Corticotropin, Cortisone, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Deflazacort, Dexamethasone (Systemic), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fludrocortisone, Fluorouracil (Systemic), Fluticasone (Oral Inhalation), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydrocortisone (Systemic), Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Leflunomide, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MethylPREDNISolone, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, PrednisoLONE (Systemic), PredniSONE, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Triamcinolone (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine<br><b>Exception</b> Cytarabine (Liposomal)</p>\n</div> \n<p><b>Discussion</b> Data in the trastuzumab prescribing information show possible synergistic effects of trastuzumab on the incidence of leukopenia and anemia when combined either with paclitaxel or with an anthracycline and cyclophosphamide (A+C).<sup>1</sup> The reported incidence of leukopenia was 3% with trastuzumab alone, but 24% with paclitaxel (17% with paclitaxel alone) and 52% with A+C (34% with A+C alone). Similarly, the reported incidence of anemia was 4% with trastuzumab alone, but 14% with paclitaxel (9% with paclitaxel alone) and 36% with A+C (26% with A+C alone).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Herceptin (trastuzumab). South San Francisco, CA: Genentech, Inc., May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4414":"<p><b>Title</b> Factor VIIa (Recombinant) / Aminocaproic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Aminocaproic Acid may enhance the thrombogenic effect of Factor VIIa (Recombinant). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Both aminocaproic acid and recombinant coagulation factor VIIa act to promote thrombosis, resulting in potential concern regarding excess thrombosis risk if these agents are used in combination. Though specific studies of the combination are lacking, factor VIIa prescribing information warns of the possible interaction with aminocaproic acid (and other thrombosis-enhancing products), but states that such combinations have been used safely in at least 50 patients.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. NovoSeven (coagulation factor VIIa). Princeton, NJ: Novo Nordisk Inc., October 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4415":"<p><b>Title</b> Fexofenadine / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Grapefruit Juice may decrease the serum concentration of Fexofenadine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patient for decreased effects of fexofenadine with concomitant administration of grapefruit or other fruit juices. Separating fexofenadine administration and grapefruit juice consumption by at least 4 hours may decrease the significance of this possible interaction.</p> \n<p><b>Discussion</b> Data from several studies suggest that grapefruit juice (GFJ) inhibits the absorption of fexofenadine, with a mechanism that appears to involve competitive inhibition of the OATP1A2 uptake transporter that normally assists absorption of fexofenadine. In one study of 12 healthy volunteers, GFJ and a naringin (bitter component of GFJ) solution each decreased fexofenadine (120mg) AUC (by 45% and 25%, respectively).<sup>1</sup> In another study of 12 volunteers, GFJ significantly decreased fexofenadine (120mg) AUC when coadministered (decreased by 52%), but the effect was time-dependent, where administration 2 hours prior to fexofenadine decreased AUC 38% and administration 4 hours prior did not significantly decrease AUC (only 4% decrease).<sup>2</sup> Fexofenadine prescribing information states that concomitant administration with grapefruit juice or other fruit juices may decrease the bioavailability of fexofenadine by 36%.<sup>3</sup> This interaction may likely result from the inhibition of an organic anion transporting peptide (OATP) by fruit juices (and specifically OATP1A2). Inhibition of this transporter would likely lead to a reduction in the uptake and bioavailability of fexofenadine. Separate in vitro studies have demonstrated the OATP-mediated uptake of fexofenadine.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bailey DG, Dresser GK, Leake BF, et al, “Naringin Is a Major and Selective Clinical Inhibitor of Organic Anion-Transporting Polypeptide 1A2 (OATP1A2) in Grapefruit Juice,” <i>Clin Pharmacol Ther</i>, 2007, 81:495-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17301733\">[PubMed 17301733]</a> </p>\n<p>2. Glaeser H, Bailey DG, Dresser GK, et al, “Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans,” <i>Clin Pharmacol Ther</i>, 2007, 81:362-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17215845\">[PubMed 17215845]</a> </p>\n<p>3. Prescribing information. Allegra (fexofenadine). Bridgewater, NJ: Sanofi-Aventis, July 2007.</p>\n<p>4. Cvetkovic M, Leake B, Fromm MF, et al, “OATP and P-Glycoprotein Transporters Mediate The Cellular Uptake and Excretion of Fexofenadine,” <i>Drug Metabolism and Disposition</i>, 1999,277(8):866-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10421612\">[PubMed 10421612]</a> </p>\n<p>5. Dresser GK, Bailey DG, Leake BF, et al, “Fruit Juices Inhibit Organic Anion Transporting Polypeptide-Mediated Drug Uptake to Decrease the Oral Availability of Fexofenadine,” <i>Clinical Pharmacology &amp; Therapeutics</i>, 2002,71(1):11-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11823753\">[PubMed 11823753]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4418":"<p><b>Title</b> Tamoxifen / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concurrent use of strong CYP2D6 inhibitors with tamoxifen when possible as the combination may be associated with a reduced clinical effectiveness of tamoxifen.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Numerous studies have shown that decreased CYP2D6 activity (secondary to genetic variants<sup>1,2,3,4,5,6,7,8,9,10,11</sup> and/or drug interactions<sup>3,12</sup>) in patients taking tamoxifen is associated with decreased disease-/progression-free survival,<sup>1,2,3,4,6,7,8,9,10,11,12</sup> more recurrences,<sup>2,8,10</sup> nonresponse to therapy,<sup>5</sup> and fewer hot flashes.<sup>4</sup> These poor outcomes are likely the result of decreased concentrations of the highly antiestrogenic tamoxifen metabolites 4-hydroxy-tamoxifen and 4-hydroxy-N-desmethyl-tamoxifen (endoxifen),<sup>1,2,3,4,5,6,7,8,9,10,11,12</sup> both of which are highly dependent on CYP2D6 for their formation.<sup>13,14</sup> Although the preponderance of published evidence points to an association between CYP2D6 activity and tamoxifen outcomes, a few studies have found no association. <sup>15,16,17,18 </sup> <br><br>Studies examining tamoxifen pharmacokinetics when coadministered with strong CYP2D6 inhibitors have shown 58-72% reductions in endoxifen concentrations with concurrent CYP2D6 inhibitors.<sup>16,17,18</sup> Not surprisingly, this effect is more significant in patients without genetic variants that diminish their baseline CYP2D6 activity, as one study showed a 64% reduction in endoxifen concentrations among CYP2D6 extensive metabolizers (i.e., “normal” gene coding for CYP2D6) versus only a 24% reduction among CYP2D6 poor metabolizers (i.e., mutation in gene encoding CYP2D6) with a concurrent CYP2D6 inhibitor.<sup>18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Xu Y, Sun Y, Yao L, et al, “Association between CYP2D6 *10 Genotype and Survival of Breast Cancer Patients Receiving Tamoxifen Treatment,” <i>Ann Oncol</i>, 2008, 19(8):1423-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18407954\">[PubMed 18407954]</a></p>\n<p>2. Schroth W, Antoniadou L, Fritz P, et al, “Breast Cancer Treatment Outcome with Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes,” <i>J Clin Oncol</i>, 2007, 25:5187-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18024866\">[PubMed 18024866]</a></p>\n<p>3. Goetz MP, Knox SK, Suman VJ, et al, “The Impact of Cytochrome P450 2D6 Metabolism in Women Receiving Adjuvant Tamoxifen,” <i>Breast Cancer Res Treat</i>, 2007, 101:113-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17115111\">[PubMed 17115111]</a></p>\n<p>4. Goetz MP, Rae JM, Suman VJ, et al, “Pharmacogenetics of Tamoxifen Biotransformation Is Associated with Clinical Outcomes of Efficacy and Hot Flashes,” <i>J Clin Oncol</i>, 2005, 23:9312-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16361630\">[PubMed 16361630]</a></p>\n<p>5. Lim HS, Ju Lee H, Seok Lee K, et al, “Clinical Implications of CYP2D6 Genotypes Predictive of Tamoxifen Pharmacokinetics in Metastatic Breast Cancer,” <i>J Clin Oncol</i>, 2007, 25:3837-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17761971\">[PubMed 17761971]</a></p>\n<p>6. Kiyotani K, Mushiroda T, Sasa M, et al, “Impact of CYP2D6*10 on Recurrence-Free Survival in Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy,” <i>Cancer Sci,</i> 2008, 99(5):995-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18294285\">[PubMed 18294285]</a></p>\n<p>7. Goetz MP, Suman VJ, Couch FJ, et al, “Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance,” <i>Clin Cancer Res,</i> 2008, 14(18):5864-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18794098\">[PubMed 18794098]</a></p>\n<p>8. Kiyotani K, Mushiroda T, Imamura CK, et al, “Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients,” <i>J Clin Oncol,</i> 2010, Epub ahead of print. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20124171\">[PubMed 20124171]</a></p>\n<p>9. Ramon y Cajal T, Altes A, Pare L, et al, “Impact of CYP2D6 Polymorphisms in Tamoxifen Adjuvant Breast Cancer Treatment,” <i>Breast Cancer Res Treat,</i> 2010, 119(1):33-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19189210\">[PubMed 19189210]</a></p>\n<p>10. Schroth W, Goetz MP, Hamann U, “Association Between CYP2D6 Polymorphisms and Outcomes among Women with Early Stage Breast Cancer Treated with Tamoxifen,” <i>JAMA,</i> 2009, 302(13):1429-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19809024\">[PubMed 19809024]</a></p>\n<p>11. Bijl MJ, van Schaik RH, Lammers LA, et al, “The CYP2D6*4 Polymorphism Affects Breast Cancer Survival in Tamoxifen Users,” <i>Breast Cancer Res Treat,</i> 2009, 118(1):125-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19189212\">[PubMed 19189212]</a></p>\n<p>12. Kelly CM, Juurlink DN, Gomes T, et al, “Selective Serotonin Reuptake Inhibitors and Breast Cancer Mortality in Women Receiving Tamoxifen: a Population Based Cohort Study,” <i>BMJ,</i> 2010, 340:c693. doi: 10.1136/bmj.c693. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20142325\">[PubMed 20142325]</a></p>\n<p>13. Crewe HK, Notley LM, Wunsch RM, et al, “Metabolism of Tamoxifen by Recombinant Human Cytochrome P450 Enzymes: Formation of the 4-Hydroxy, 4'-Hydroxy and N-Desmethyl Metabolites and Isomerization of Trans-4-Hydroxytamoxifen,” <i>Drug Metab Dispos</i>, 2002, 30:869-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12124303\">[PubMed 12124303]</a></p>\n<p>14. Desta Z, Ward BA, Soukhova NV, et al, “Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6,” <i>J Pharmacol Exp Ther</i>, 2004, 310:1062-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15159443\">[PubMed 15159443]</a></p>\n<p>15. Lynn Henry N, Rae JM, Li L, Azzouz F, “Association between CYP2D6 Genotype and Tamoxifen-Induced Hot Flashes in a Prospective Cohort,” <i>Breast Cancer Res Treat,</i> 2009, 117(3):571-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19153830\">[PubMed 19153830]</a></p>\n<p>16. Borges S, Desta Z, Li L, et al, “Quantitative Effect of CYP2D6 Genotype and Inhibitors on Tamoxifen Metabolism: Implication for Optimization of Breast Cancer Treatment,” <i>Clin Pharmacol Ther</i>, 2006, 80:61-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16815318\">[PubMed 16815318]</a></p>\n<p>17. Jin Y, Desta Z, Stearns V, et al, “CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment,” <i>J Natl Cancer Inst</i>, 2005, 97:30-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15632378\">[PubMed 15632378]</a></p>\n<p>18. Stearns V, Johnson MD, Rae JM, et al, “Active Tamoxifen Metabolite Plasma Concentrations after Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine,” <i>J Natl Cancer Inst</i>, 2003, 95:1758-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14652237\">[PubMed 14652237]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4419":"<p><b>Title</b> Tamoxifen / CYP2D6 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Moderate CYP2D6 inhibitors may reduce the clinical effectiveness of tamoxifen; consider alternative therapy with less of an effect on CYP2D6 activity when possible.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n</div> \n<p><b>Discussion</b> Numerous studies have shown that decreased CYP2D6 activity (secondary to genetic variants<sup>1,2,3,4,5,6,7,8,9,10,11</sup> and/or drug interactions<sup>3,12</sup>) in patients taking tamoxifen is associated with decreased disease-/progression-free survival,<sup>1,2,3,4,6,7,8,9,10,11,12</sup> more recurrences,<sup>2,8,10</sup> nonresponse to therapy,<sup>5</sup> and fewer hot flashes.<sup>4</sup> These poor outcomes are likely the result of decreased concentrations of the highly antiestrogenic tamoxifen metabolites 4-hydroxy-tamoxifen and 4-hydroxy-N-desmethyl-tamoxifen (endoxifen),<sup>1,2,3,4,5,6,7,8,9,10,11,12</sup> both of which are highly dependent on CYP2D6 for their formation.<sup>13,14</sup> Although the preponderance of published evidence points to an association between CYP2D6 activity and tamoxifen outcomes, a few studies have found no association.<sup>15,16,17,18 </sup> <br><br>Studies examining tamoxifen pharmacokinetics when coadministered with strong CYP2D6 inhibitors have shown 58-72% reductions in endoxifen concentrations with concurrent CYP2D6 inhibitors.<sup>16,17,18</sup> Not surprisingly, this effect is more significant in patients without genetic variants that diminish their baseline CYP2D6 activity, as one study showed a 64% reduction in endoxifen concentrations among CYP2D6 extensive metabolizers (i.e., “normal” gene coding for CYP2D6) versus only a 24% reduction among CYP2D6 poor metabolizers (i.e., mutation in gene encoding CYP2D6) with a concurrent CYP2D6 inhibitor.<sup>18</sup> Studies with more moderate inhibitors of CYP2D6 are not available, but given the apparent clinical importance of endoxifen and 4-OH-tamoxifen concentrations, consider avoiding even moderate CYP2D6 inhibitors when possible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Xu Y, Sun Y, Yao L, et al, “Association between CYP2D6 *10 Genotype and Survival of Breast Cancer Patients Receiving Tamoxifen Treatment,” <i>Ann Oncol</i>, 2008, 19(8):1423-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18407954\">[PubMed 18407954]</a></p>\n<p>2. Schroth W, Antoniadou L, Fritz P, et al, “Breast Cancer Treatment Outcome with Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes,” <i>J Clin Oncol</i>, 2007, 25:5187-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18024866\">[PubMed 18024866]</a></p>\n<p>3. Goetz MP, Knox SK, Suman VJ, et al, “The Impact of Cytochrome P450 2D6 Metabolism in Women Receiving Adjuvant Tamoxifen,” <i>Breast Cancer Res Treat</i>, 2007, 101:113-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17115111\">[PubMed 17115111]</a></p>\n<p>4. Goetz MP, Rae JM, Suman VJ, et al, “Pharmacogenetics of Tamoxifen Biotransformation Is Associated with Clinical Outcomes of Efficacy and Hot Flashes,” <i>J Clin Oncol</i>, 2005, 23:9312-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16361630\">[PubMed 16361630]</a></p>\n<p>5. Lim HS, Ju Lee H, Seok Lee K, et al, “Clinical Implications of CYP2D6 Genotypes Predictive of Tamoxifen Pharmacokinetics in Metastatic Breast Cancer,” <i>J Clin Oncol</i>, 2007, 25:3837-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17761971\">[PubMed 17761971]</a></p>\n<p>6. Kiyotani K, Mushiroda T, Sasa M, et al, “Impact of CYP2D6*10 on Recurrence-Free Survival in Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy,” <i>Cancer Sci,</i> 2008, 99(5):995-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18294285\">[PubMed 18294285]</a></p>\n<p>7. Goetz MP, Suman VJ, Couch FJ, et al, “Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance,” <i>Clin Cancer Res,</i> 2008, 14(18):5864-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18794098\">[PubMed 18794098]</a></p>\n<p>8. Kiyotani K, Mushiroda T, Imamura CK, et al, “Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients,” <i>J Clin Oncol,</i> 2010, Epub ahead of print. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20124171\">[PubMed 20124171]</a></p>\n<p>9. Ramon y Cajal T, Altes A, Pare L, et al, “Impact of CYP2D6 Polymorphisms in Tamoxifen Adjuvant Breast Cancer Treatment,” <i>Breast Cancer Res Treat,</i> 2010, 119(1):33-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19189210\">[PubMed 19189210]</a></p>\n<p>10. Schroth W, Goetz MP, Hamann U, “Association Between CYP2D6 Polymorphisms and Outcomes among Women with Early Stage Breast Cancer Treated with Tamoxifen,” <i>JAMA,</i> 2009, 302(13):1429-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19809024\">[PubMed 19809024]</a></p>\n<p>11. Bijl MJ, van Schaik RH, Lammers LA, et al, “The CYP2D6*4 Polymorphism Affects Breast Cancer Survival in Tamoxifen Users,” <i>Breast Cancer Res Treat,</i> 2009, 118(1):125-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19189212\">[PubMed 19189212]</a></p>\n<p>12. Kelly CM, Juurlink DN, Gomes T, et al, “Selective Serotonin Reuptake Inhibitors and Breast Cancer Mortality in Women Receiving Tamoxifen: a Population Based Cohort Study,” <i>BMJ,</i> 2010, 340:c693. doi: 10.1136/bmj.c693. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20142325\">[PubMed 20142325]</a></p>\n<p>13. Crewe HK, Notley LM, Wunsch RM, et al, “Metabolism of Tamoxifen by Recombinant Human Cytochrome P450 Enzymes: Formation of the 4-Hydroxy, 4'-Hydroxy and N-Desmethyl Metabolites and Isomerization of Trans-4-Hydroxytamoxifen,” <i>Drug Metab Dispos</i>, 2002, 30:869-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12124303\">[PubMed 12124303]</a></p>\n<p>14. Desta Z, Ward BA, Soukhova NV, et al, “Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6,” <i>J Pharmacol Exp Ther</i>, 2004, 310:1062-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15159443\">[PubMed 15159443]</a></p>\n<p>15. Lynn Henry N, Rae JM, Li L, Azzouz F, “Association between CYP2D6 Genotype and Tamoxifen-Induced Hot Flashes in a Prospective Cohort,” <i>Breast Cancer Res Treat,</i> 2009, 117(3):571-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19153830\">[PubMed 19153830]</a></p>\n<p>16. Borges S, Desta Z, Li L, et al, “Quantitative Effect of CYP2D6 Genotype and Inhibitors on Tamoxifen Metabolism: Implication for Optimization of Breast Cancer Treatment,” <i>Clin Pharmacol Ther</i>, 2006, 80:61-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16815318\">[PubMed 16815318]</a></p>\n<p>17. Jin Y, Desta Z, Stearns V, et al, “CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment,” <i>J Natl Cancer Inst</i>, 2005, 97:30-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15632378\">[PubMed 15632378]</a></p>\n<p>18. Stearns V, Johnson MD, Rae JM, et al, “Active Tamoxifen Metabolite Plasma Concentrations after Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine,” <i>J Natl Cancer Inst</i>, 2003, 95:1758-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14652237\">[PubMed 14652237]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4420":"<p><b>Title</b> Vinorelbine / PACLitaxel (Protein Bound)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> PACLitaxel (Protein Bound) may enhance the neurotoxic effect of Vinorelbine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for signs and symptoms of neurotoxicity in all patients receiving both vinorelbine and protein bound paclitaxel either in combination or sequentially.</p> \n<p><b>Discussion</b> Data specific to protein bound paclitaxel and vinorelbine are not available, but it is expected that protein bound paclitaxel may possess the same risk for interacting with vinorelbine as non-protein bound paclitaxel. The data described below refer to the non-protein bound paclitaxel product.<br><br>Several clinical trials have reported neurotoxicity associated with the combination of vinorelbine (30mg/m<sup>2</sup> x1-2 doses within 2-4 weeks) and paclitaxel (135-175mg/m<sup>2</sup> every 2-4 weeks) at rates of 41-67% (all grades),<sup>1,2,3,4</sup> which is substantially greater than rates reported in the vinorelbine prescribing information (25% for all grades).<sup>5</sup> Numerous reports of serious neurotoxicity have also been published including several case reports,<sup>6,7,8</sup> phase I/II studies where neurotoxicity was the primary dose-limiting toxicity (dose-finding studies for paclitaxel in combination with fixed dose vinorelbine),<sup>9,10</sup> and one clinical trial of vinorelbine plus paclitaxel plus carboplatinum where 16% of patients reported grade 3-4 neurotoxicity<sup>11</sup> (vs. 1% rate of grade 3-4 neurotoxicity in vinorelbine prescribing information<sup>5</sup>).<br><br>In contrast to these reports, others have reported relatively low rates of neurotoxicity with the use of combined (either concurrent use or sequential use) vinorelbine and paclitaxel.<sup>12,13,14</sup> Whether these reports reflect variations in dosing schedule, concurrent/prior medication exposure, patient characteristics, and/or other variable factors is unclear.<br><br>Both paclitaxel and vinorelbine are individually associated with a risk of neurotoxicity, but the precise mechanism by which the combination may contribute to an elevated risk of neurotoxicity is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ballestrero A, Montemurro F, Gonella R, et al, “Dose-Dense Vinorelbine and Paclitaxel with Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer Patients: Anti-Tumor Activity and Peripheral Blood Progenitor Cell Mobilization Capability,” <i>Breast Cancer Res Treat</i>, 2003, 82:185-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14703065\">[PubMed 14703065]</a> </p>\n<p>2. Perez JE, Machiavelli MR, Romero AO, et al, “Vinorelbine and Paclitaxel for Locoregional Advanced or Metastatic Non-Small-Cell Lung Cancer,” <i>Am J Clin Oncol</i>, 2002, 25:383-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12151970\">[PubMed 12151970]</a> </p>\n<p>3. Romero Acuna L, Langhi M, Perez J, et al, “Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Cancer,” <i>J Clin Oncol</i>, 1999, 17:74-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10458220\">[PubMed 10458220]</a> </p>\n<p>4. Martin M, Casado A, Perez Segura P, et al, “Paclitaxel Plus Vinorelbine in Metastatic Breast Ca Patients with Contraindications to Receive Anthracyclines,” <i>Oncology (Williston Park)</i>, 1998, 12:28-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9516600\">[PubMed 9516600]</a> </p>\n<p>5. Prescribing information. Navelbine (vinorelbine). Parsippany, NJ: Pierre-Fabre Pharmaceuticals Inc., July 2006.</p>\n<p>6. Scalone S, Sorio R, Bortolussi R, et al, “Vinorelbine-Induced Acute Reversible Peripheral Neuropathy in a Patient with Ovarian Carcinoma Pretreated with Carboplatin and Paclitaxel,” <i>Acta Oncol</i>, 2004, 43:209-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15163172\">[PubMed 15163172]</a> </p>\n<p>7. Han JY, Choi BG, Song DH, et al, “Vinorelbine-Associated Myelopathy in a Patient Who Previously Received Paclitaxel: A Case Report,” <i>Med Oncol</i>, 2001, 18:95-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11778975\">[PubMed 11778975]</a> </p>\n<p>8. Parimoo D, Jeffers S,Muggia FM, “Severe Neurotoxicity from Vinorelbine-Paclitaxel Combinations,” <i>J Natl Cancer Inst</i>, 1996, 88:1079-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8683640\">[PubMed 8683640]</a> </p>\n<p>9. Iaffaioli RV, Facchini G, Tortoriello A, et al, “Phase I Study of Vinorelbine and Paclitaxel in Small-Cell Lung Cancer,” <i>Cancer Chemother Pharmacol</i>, 1997, 41:86-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9443619\">[PubMed 9443619]</a> </p>\n<p>10. Tortoriello A, Facchini G, Caponigro F, et al, “Phase I/II Study of Paclitaxel and Vinorelbine in Metastatic Breast Cancer,” <i>Breast Cancer Res Treat</i>, 1998, 47:91-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9493980\">[PubMed 9493980]</a> </p>\n<p>11. Schmittel A, Siehl JM, Schulze M, et al, “Phase II Trial of Carboplatin, Paclitaxel Plus Vinorelbine in Non-Small Cell Lung Cancer Patients,” <i>Anticancer Res</i>, 2005, 25:1333-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15865087\">[PubMed 15865087]</a> </p>\n<p>12. Fleming GF, Waggoner SE, Rotmensch J, et al, “Absence of Major Peripheral Neuropathy in a Phase Ii Trial of Ifosfamide with Vinorelbine in Patients with Ovarian Cancer Previously Treated with Platinum and Paclitaxel,” <i>Am J Clin Oncol</i>, 2001, 24:52-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11232950\">[PubMed 11232950]</a> </p>\n<p>13. Budman DR, Weiselberg L,O'Mara V, “Re: Severe Neurotoxicity in Vinorelbine-Paclitaxel Combinations,” <i>J Natl Cancer Inst</i>, 1997, 89:87-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8978412\">[PubMed 8978412]</a> </p>\n<p>14. Budman DR, Weiselberg L, O'Mara V, et al, “A Phase I Study of Sequential Vinorelbine Followed by Paclitaxel,” <i>Ann Oncol</i>, 1999, 10:861-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10470436\">[PubMed 10470436]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4421":"<p><b>Title</b> Indinavir / Atovaquone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Atovaquone may decrease the serum concentration of Indinavir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to indinavir when used in combination with atovaquone, as indinavir minimum concentrations may be reduced, potentially compromising its clinical effectiveness.</p> \n<p><b>Discussion</b> Data presented in atovaquone/proguanil prescribing information state that the combination of atovaquone (750mg BID x 14 days) with indinavir (800mg TID x 14 days) was associated with an average 23% reduction in indinavir minimum concentration.<sup>1</sup> Indinavir AUC and maximum concentration were unchanged. The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Malarone (atovaquone and proguanil). Research Triangle Park, NC: GlaxoSmithKline, June 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4422":"<p><b>Title</b> Desmopressin / Lithium</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lithium may diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to desmopressin closely when used together with lithium. Also, watch for signs and symptoms of lithium toxicity and consider increased monitoring of lithium concentrations during concurrent therapy with desmopressin.</p> \n<p><b>Discussion</b> Four weeks of lithium carbonate (250mg BID) had a small but statistically significant negative effect on the clinical response to desmopressin (40mcg) in a study of 11 healthy volunteers.<sup>1</sup> Desmopressin-induced increase in urinary osmolality was reduced by 5.1%, and urinary excretion of the vasopressin-regulated water channel aquaporin-2 (AQP2) was reduced by 21.6%. Similarly, a study of 20 patients receiving long-term lithium found a decreased response to desmopressin.<sup>2</sup> Lithium has also long been considered a treatment option for patients with signs and symptoms of antidiuretic hormone excess, such as those with Syndrome of Inappropriate Antidiuretic Hormone (SIADH), based largely on its ability to antagonize the actions of vasopressin.<sup>3,4,5</sup> <br><br>The mechanism of this interaction was attributed to decreased translocation of AQP2 from the cytoplasm, interfering with the ability of AQP2 to promote water reabsorption.<sup>1</sup> Animal data showing that lithium induces a downregulation of AQP2 expression, and that this effect is only partially reversed by desmopressin,<sup>6</sup> support this hypothesis. Other data show that lithium does not alter the binding affinity of vasopressin for its receptors, but does decrease the density of vasopressin receptors.<sup>7</sup><br><br>Additionally, evidence exists that desmopressin may alter the pharmacokinetics of lithium. A study in 8 healthy volunteers showed that desmopressin decreased the fractional renal excretion of lithium by approximately 20% (from 27.9% to 22.4%).<sup>8</sup> These data support results from a study in rats that showed a decrease in lithium reabsorption caused by concurrent desmopressin.<sup>9</sup> The exact mechanism and clinical significance of this interaction are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Walker RJ, Weggery S, Bedford JJ, et al, “Lithium-Induced Reduction in Urinary Concentrating Ability and Urinary Aquaporin 2 (AQP2) Excretion in Healthy Volunteers,” <i>Kidney Int</i>, 2005, 67:291-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15610254\">[PubMed 15610254]</a> </p>\n<p>2. Wilting I, Baumgarten R, Movig KL, et al, “Urine Osmolality, Cyclic Amp and Aquaporin-2 in Urine of Patients under Lithium Treatment in Response to Water Loading Followed by Vasopressin Administration,” <i>Eur J Pharmacol</i>, 2007, 566:50-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17466972\">[PubMed 17466972]</a> </p>\n<p>3. Kinzie BJ, “Management of the Syndrome of Inappropriate Secretion of Antidiuretic Hormone,” <i>Clin Pharm</i>, 1987, 6:625-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3121240\">[PubMed 3121240]</a> </p>\n<p>4. Finsterer U, Beyer A, Jensen U, et al, “The Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH)--Treatment with Lithium,” <i>Intensive Care Med</i>, 1982, 8:223-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6813362\">[PubMed 6813362]</a> </p>\n<p>5. White MG,Fetner CD, “Treatment of the Syndrome of Inappropriate Secretion of Antidiuretic Hormone with Lithium Carbonate,” <i>N Engl J Med</i>, 1975, 292:390-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1110724\">[PubMed 1110724]</a> </p>\n<p>6. Marples D, Christensen S, Christensen EI, et al, “Lithium-Induced Downregulation of Aquaporin-2 Water Channel Expression in Rat Kidney Medulla,” <i>J Clin Invest</i>, 1995, 95:1838-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7535800\">[PubMed 7535800]</a> </p>\n<p>7. Hensen J, Haenelt M,Gross P, “Lithium Induced Polyuria and Renal Vasopressin Receptor Density,” <i>Nephrol Dial Transplant</i>, 1996, 11:622-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8671849\">[PubMed 8671849]</a> </p>\n<p>8. Bijlsma JA, Koomans HA, Boer WH, et al, “Indomethacin- and Desamino-8-D-Arginine Vasopressin-Induced Lithium Reabsorption Is Not Amiloride Sensitive in Humans,” <i>J Pharmacol Exp Ther</i>, 1993, 265:1267-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8510007\">[PubMed 8510007]</a> </p>\n<p>9. Walter SJ, Shirley DG,Unwin RJ, “Effect of Vasopressin on Renal Lithium Reabsorption: A Micropuncture and Microperfusion Study,” <i>Am J Physiol</i>, 1996, 271:F223-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8760265\">[PubMed 8760265]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4423":"<p><b>Title</b> Linezolid / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Linezolid. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid using linezolid in any patient currently receiving a monoamine oxidase inhibitor as well as in any patient who has received a monoamine oxidase inhibitor within the previous 2 weeks.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> According to linezolid prescribing information linezolid should not be used with any drugs that inhibit monoamine oxidase (MAO) (including MAO-A or MAO-B) as well as within two weeks of taking any such drug.<sup>1</sup> Linezolid has been reported to possess some intrinsic MAO inhibitory effects and has been associated with adverse effects such as hypertension and serotonin syndrome related to this effect.<sup>1</sup> Whether this property is related to this labeled contraindication is not specified.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zyvox (linezolid). New York, NY: Pfizer Inc, May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4424":"<p><b>Title</b> Desmopressin / Demeclocycline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Demeclocycline may diminish the therapeutic effect of Desmopressin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to desmopressin closely when used together with demeclocycline.</p> \n<p><b>Discussion</b> Several case reports and clinical studies show that demeclocycline effectively antagonizes the actions of endogenous vasopressin,<sup>1,2,3,4,5,6,7</sup> suggesting that demeclocycline could similarly antagonize the actions of desmopressin (a synthetic version of vasopressin). Demeclocycline has been reported as an effective treatment of vasopressin excess in a variety of clinical settings, including (but not necessarily limited to) in perioperative patients,<sup>1</sup> secondary to carbamazepine treatment,<sup>2,3</sup> and in patients with Syndrome of Inappropriate Antidiuretic Hormone (SIADH).<sup>4,5,6,7</sup><br><br>The precise mechanism by which demeclocycline antagonizes the actions of vasopressin (and possibly desmopressin) is unclear. It has been suspected that demeclocycline blocks vasopressin binding to its receptor,<sup>8</sup> and demeclocycline has been shown to decrease antidiuretic hormone-sensitive adenylate cyclase activity in renal collecting ducts.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Horattas MC, Evasovich MR, Muakkassa FF, et al, “Perioperative Vasopressin Secretion Treated by Demeclocycline,” <i>Am Surg</i>, 1998, 64:281-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9520826\">[PubMed 9520826]</a> </p>\n<p>2. Ringel RA,Brick JF, “Perspective on Carbamazepine-Induced Water Intoxication: Reversal by Demeclocycline,” <i>Neurology</i>, 1986, 36:1506-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3093919\">[PubMed 3093919]</a> </p>\n<p>3. Ballardie FW,Mucklow JC, “Partial Reversal of Carbamazepine-Induced Water Intolerance by Demeclocycline,” <i>Br J Clin Pharmacol</i>, 1984, 17:763-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6430315\">[PubMed 6430315]</a> </p>\n<p>4. Cherrill DA, Stote RM, Birge JR, et al, “Demeclocycline Treatment in the Syndrome of Inappropriate Antidiuretic Hormone Secretion,” <i>Ann Intern Med</i>, 1975, 83:654-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=173218\">[PubMed 173218]</a> </p>\n<p>5. Forrest JN, Jr., Cox M, Hong C, et al, “Superiority of Demeclocycline over Lithium in the Treatment of Chronic Syndrome of Inappropriate Secretion of Antidiuretic Hormone,” <i>N Engl J Med</i>, 1978, 298:173-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=413037\">[PubMed 413037]</a> </p>\n<p>6. Perks WH, Walters EH, Tams IP, et al, “Demeclocycline in the Treatment of the Syndrome of Inappropriate Secretion of Antidiuretic Hormone,” <i>Thorax</i>, 1979, 34:324-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=113900\">[PubMed 113900]</a> </p>\n<p>7. De Troyer A, “Demeclocycline. Treatment for Syndrome of Inappropriate Antidiuretic Hormone Secretion,” <i>JAMA</i>, 1977, 237:2723-6.</p>\n<p>8. De Troyer A, Demanet JC, “Correction of Antidiuresis by Demeclocycline,” <i>N Engl J Med</i>, 1975, 293 (18): 915-8.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4425":"<p><b>Title</b> Desmopressin / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may enhance the adverse/toxic effect of Desmopressin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When using desmopressin and carbamazepine concurrently, monitor patients closely for signs and symptoms of water intoxication, hyponatremia, or other complications of excessive antidiuretic effects.</p> \n<p><b>Discussion</b> Major complications (including those associated with water intoxication) were more common in desmopressin-treated patients who were also receiving carbamazepine than in those not on concurrent carbamazepine (33% vs. 10%) in a retrospective review of 103 desmopressin-treated patients.<sup>1</sup> Desmopressin prescribing information warns that caution should be exercised when considering the use of desmopressin concurrently with carbamazepine due to the risk of water intoxication and hyponatremia.<sup>2</sup> A similar caution is urged concerning the combination of desmopressin with any other medication that may increase the risk of water intoxication with hyponatremia.<br><br>Several reports have described cases of water intoxication,<sup>3,4,5</sup> abnormal water metabolism,<sup>6</sup> and Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH)<sup>7</sup> that were attributed to carbamazepine treatment.<br><br>The precise mechanism by which carbamazepine appears to enhance endogenous vasopressin activity is unclear. Several studies examining plasma vasopressin concentrations with exposure to carbamazepine have reported a decrease in vasopressin concentrations after carbamazepine treatment,<sup>6,8,9</sup> though in reports of carbamazepine-induced water intoxication, affected patients have had low,<sup>3</sup> normal,<sup>4</sup> and elevated<sup>5</sup> vasopressin concentrations. Together with other available data, these variable plasma vasopressin concentrations suggest carbamazepine has a vasopressin-like effect and/or that carbamazepine increases the sensitivity of the vasopressin receptor.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rizzo V, Albanese A, Stanhope R, “Morbidity and Mortality Associated with Vasopressin Replacement Therapy in Children,” <i>J Pediatr Endocrinol Metab</i>, 2001, 14(7):861-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11515726\">[PubMed 11515726]</a> </p>\n<p>2. Prescribing information. DDAVP (desmopressin). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, July 2007.</p>\n<p>3. Ballardie FW,Mucklow JC, “Partial Reversal of Carbamazepine-Induced Water Intolerance by Demeclocycline,” <i>Br J Clin Pharmacol</i>, 1984, 17:763-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6430315\">[PubMed 6430315]</a></p>\n<p>4. Ringel RA, Brick JF, “Perspective on Carbamazepine-Induced Water Intoxication: Reversal by Demeclocycline,” <i>Neurology</i>, 1986, 36:1506-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3093919\">[PubMed 3093919]</a> </p>\n<p>5. Smith NJ, Espir ML,Baylis PH, “Raised Plasma Arginine Vasopressin Concentration in Carbamazepine-Induced Water Intoxication,” <i>Br Med J</i>, 1977, 2:804. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=912329\">[PubMed 912329]</a> </p>\n<p>6. Stephens WP, Coe JY,Baylis PH, “Plasma Arginine Vasopressin Concentrations and Antidiuretic Action of Carbamazepine,” <i>Br Med J</i>, 1978, 1:1445-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=647329\">[PubMed 647329]</a> </p>\n<p>7. Sordillo P, Sagransky DM, Mercado RM, et al, “Carbamazepine-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion. Reversal by Concomitant Phenytoin Therapy,” <i>Arch Intern Med</i>, 1978, 138:299-301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=626557\">[PubMed 626557]</a> </p>\n<p>8. Krause KH, Rascher W,Berlit P, “Plasma Arginine Vasopressin Concentrations in Epileptics under Monotherapy,” <i>J Neurol</i>, 1983, 230:193-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6197514\">[PubMed 6197514]</a> </p>\n<p>9. Thomas TH, Ball SG, Wales JK, et al, “Effect of Carbamazepine on Plasma and Urine Arginine-Vasopressin,” <i>Clin Sci Mol Med</i>, 1978, 54:419-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=639473\">[PubMed 639473]</a> </p>\n<p>10. Tormey WP, “Mechanisms of Carbamazepine-Induced Antidiuresis,” <i>J Neurol Neurosurg Psychiatry</i>, 1993, 56:567. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8505653\">[PubMed 8505653]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4426":"<p><b>Title</b> Desmopressin / Tricyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when using desmopressin and tricyclic antidepressants concurrently, and monitor patients closely for signs and symptoms of water intoxication, hyponatremia, or other complications of excessive antidiuretic effects.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> Desmopressin prescribing information warns that caution should be exercised when considering the use of desmopressin concurrently with any other medication that may increase the risk of water intoxication with hyponatremia.<sup>1</sup> Concurrent use with tricyclic antidepressants is specifically mentioned in the warning as a combination that may be associated with increased risk of water intoxication and hyponatremia.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DDAVP (desmopressin). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, July 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4427":"<p><b>Title</b> Desmopressin / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when using desmopressin and selective serotonin reuptake inhibitor (SSRI) antidepressants concurrently, and monitor patients closely for signs and symptoms of water intoxication, hyponatremia, or other complications of excessive antidiuretic effects.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n</div> \n<p><b>Discussion</b> Desmopressin prescribing information warns that caution should be exercised when considering the use of desmopressin concurrently with any other medication that may increase the risk of water intoxication with hyponatremia.<sup>1</sup> Concurrent use with selective serotonin reuptake inhibitor (SSRI) antidepressants is specifically mentioned in the warning as a combination that may be associated with increased risk of water intoxication and hyponatremia.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DDAVP (desmopressin). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, July 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4428":"<p><b>Title</b> Desmopressin / LamoTRIgine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> LamoTRIgine may enhance the adverse/toxic effect of Desmopressin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when using desmopressin and lamotrigine concurrently, and monitor patients closely for signs and symptoms of water intoxication, hyponatremia, or other complications of excessive antidiuretic effects. A case report suggests desmopressin dose adjustments may be necessary with this combination.</p> \n<p><b>Discussion</b> Decreased desmopressin dose requirements were noted in 2 young patients with cranial diabetes insipidus in whom lamotrigine was used concurrently with desmopressin.<sup>1</sup> Further, in one patient, as the lamotrigine dose was later decreased, that patient's desmopressin dose requirement increased.<br><br>Desmopressin prescribing information warns that caution should be exercised when considering the use of desmopressin concurrently with any other medication that may increase the risk of water intoxication with hyponatremia.<sup>2</sup> Concurrent use with lamotrigine is specifically mentioned in the warning as a combination that may be associated with increased risk of water intoxication and hyponatremia.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mewasingh L, Aylett S, Kirkham F, et al, “Hyponatraemia Associated with Lamotrigine in Cranial Diabetes Insipidus,” <i>Lancet</i>, 2000, 356(9230):656. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10968444\">[PubMed 10968444]</a> </p>\n<p>2. Prescribing information. DDAVP (desmopressin). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, July 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4429":"<p><b>Title</b> Desmopressin / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when using desmopressin and nonsteroidal antiinflammatory drugs (NSAIDs) concurrently, and monitor patients closely for signs and symptoms of water intoxication, hyponatremia, or other complications of excessive antidiuretic effects.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Desmopressin prescribing information warns that caution should be exercised when considering the use of desmopressin concurrently with any other medication that may increase the risk of water intoxication with hyponatremia.<sup>1</sup> Concurrent use with nonsteroidal antiinflammatory drugs (NSAIDs) is specifically mentioned in the warning as a combination that may be associated with increased risk of water intoxication and hyponatremia.<sup>1</sup><br><br>One published case describes a woman with von Willebrand's disease who experienced severe hyponatremia and low plasma osmolality (with loss of consciousness) 2 days after receiving desmopressin and ibuprofen following a dental procedure.<sup>2</sup> Several other published cases have described episodes of hyponatremia and Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) associated with NSAID use (without concurrent desmopressin).<sup>3,4,5,6,7</sup> One review of NSAID-related hyponatremia concluded that patients at highest risk of this relatively rare adverse event (apart from concurrent desmopressin use) include neonates receiving indomethacin for patent ductus arteriosus and adult patients with comorbidities that impair urinary dilution.<sup>7</sup><br><br>The precise mechanism(s) by which NSAIDs cause hyponatremia or SIADH is unclear, but it is the potential to exert such an effect that has led to warnings about their concurrent use with desmopressin, which is a vasopressin analog that alone can cause similar effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DDAVP (desmopressin). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, July 2007.</p>\n<p>2. Garcia EB, Ruitenberg A, Madretsma GS, et al, “Hyponatraemic Coma Induced by Desmopressin and Ibuprofen in a Woman with Von Willebrand's Disease,” <i>Haemophilia</i>, 2003, 9:232-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12614377\">[PubMed 12614377]</a> </p>\n<p>3. Blum M,Aviram A, “Ibuprofen Induced Hyponatraemia,” <i>Rheumatol Rehabil</i>, 1980, 19:258-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7209292\">[PubMed 7209292]</a> </p>\n<p>4. Petersson I, Nilsson G, Hansson BG, et al, “Water Intoxication Associated with Non-Steroidal Anti-Inflammatory Drug Therapy,” <i>Acta Med Scand</i>, 1987, 221:221-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3591460\">[PubMed 3591460]</a> </p>\n<p>5. Shimada T, Higashi K, Kimura K, et al, “Syndrome of Inappropriate Antidiuresis Seen Twice in Eight Years,” <i>Endocr J</i>, 1995, 42:163-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7627260\">[PubMed 7627260]</a> </p>\n<p>6. Cheung NT, Coley S, Sheeran T, et al, “Syndrome of Inappropriate Secretion of Antidiuretic Hormone Induced by Diclofenac,” <i>BMJ</i>, 1993, 306:186. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8443484\">[PubMed 8443484]</a> </p>\n<p>7. Rault RM, “Case Report: Hyponatremia Associated with Nonsteroidal Antiinflammatory Drugs,” <i>Am J Med Sci</i>, 1993, 305:318-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8484392\">[PubMed 8484392]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4430":"<p><b>Title</b> Desmopressin / Opioid Analgesics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Opioid Analgesics may enhance the adverse/toxic effect of Desmopressin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when using desmopressin and opioid analgesics concurrently, and monitor patients closely for signs and symptoms of water intoxication, hyponatremia, or other complications of excessive antidiuretic effects.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n</div> \n<p><b>Discussion</b> Desmopressin prescribing information warns that caution should be exercised when considering the use of desmopressin concurrently with any other medication that may increase the risk of water intoxication with hyponatremia.<sup>1</sup> Concurrent use with opioid analgesics is specifically mentioned in the warning as a combination that may be associated with increased risk of water intoxication and hyponatremia.<sup>1</sup> Though specific data regarding the combination of opioids and desmopressin are not available, cases of hyponatremia/syndrome of inappropriate antidiuretic hormone secretion (SIADH) associated with opioid use have been reported.<sup>2,3</sup> The specific mechanism(s) by which opioids may alter renal function and/or response to endogenous vasopressin is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DDAVP (desmopressin). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, July 2007.</p>\n<p>2. Udy A, Deacy N, Barnes D, et al, “Tramadol-Induced Hyponatraemia Following Unicompartmental Knee Replacement Surgery,” <i>Anaesthesia</i>, 2005, 60:814-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16029233\">[PubMed 16029233]</a> </p>\n<p>3. Kokko H, Hall PD, Afrin LB, “Fentanyl-Associated Syndrome of Inappropriate Antidiuretic Hormone Secretion,” <i>Pharmacotherapy</i>, 2002, 22:1188-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12222557\">[PubMed 12222557]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4431":"<p><b>Title</b> Desmopressin / ChlorproMAZINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> ChlorproMAZINE may enhance the adverse/toxic effect of Desmopressin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when using desmopressin and chlorpromazine concurrently, and monitor patients closely for signs and symptoms of water intoxication, hyponatremia, or other complications of excessive antidiuretic effects.</p> \n<p><b>Discussion</b> Desmopressin prescribing information warns that caution should be exercised when considering the use of desmopressin concurrently with any other medication that may increase the risk of water intoxication with hyponatremia.<sup>1</sup> Concurrent use with chlorpromazine is specifically mentioned in the warning as a combination that may be associated with increased risk of water intoxication and hyponatremia.<sup>1</sup> Though specific data regarding the combination of chlorpromazine and desmopressin are lacking, hyponatremia/syndrome of inappropriate antidiuretic hormone secretion (SIADH) associated with chlorpromazine use has been reported.<sup>2</sup> The specific mechanism(s) by which chlorpromazine may alter renal function and/or response to endogenous vasopressin is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DDAVP (desmopressin). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, July 2007.</p>\n<p>2. Tildesley HD, Toth E, Crockford PM, “Syndrome of Inappropriate Secretion of Antidiuretic Hormone in Association with Chlorpromazine Ingestion,” <i>Can J Psychiatry</i>, 1983, 28(6):487-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6640486\">[PubMed 6640486]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4432":"<p><b>Title</b> Anagrelide / Sucralfate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sucralfate may decrease the serum concentration of Anagrelide. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor response to anagrelide closely if used together with sucralfate. Consider separating administration of each agent in order to minimize the risk/magnitude of an interaction.</p> \n<p><b>Discussion</b> According to a statement in the anagrelide prescribing information, a single case report has described a decrease in anagrelide absorption associated with concurrent sucralfate.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Agrylin (anagrelide). Wayne, PA: Shire US Inc., 11/07.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4433":"<p><b>Title</b> Dabigatran Etexilate / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Recommendations regarding use with antacids may differ depending on international labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Dabigatran Etexilate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Dabigatran etexilate Canadian product monograph recommends avoiding concomitant use with antacids in the 24 hour period after surgery. In other situations where antacids and dabigatran are to be used together, administer dabigatran 2 hours prior to the antacid. Monitor for decreased clinical response to dabigatran therapy. Dabigatran etexilate U.S. product labeling does not include similar recommendations.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Dabigatran etexilate Canadian product monograph notes that dabigatran (active drug) exposure was reduced by 11% when administered with antacids.<sup>1</sup> The clinical significance of this change is unclear, but the product labeling does caution that a decreased clinical effect may result. It is also noted that the antacid interaction may be more substantial in the 24 hours following surgery, as a 35% reduction in dabigatran exposure was observed in post-operative patients up to 24 hours after surgery.<sup>1</sup> Due to this larger risk for a decreased clinical (anticoagulant) effect, concomitant use of antacids with dabigatran should be avoided for 24 hours following surgery. It is also recommended that dabigatran etexilate be administered 2 hours prior to antacids.<sup>1</sup> Dabigatran etexilate U.S. product labeling does not include similar recommendations.<sup>2</sup><br><br>The specific mechanism of this interaction has not been proven, particularly with regard to the greater magnitude interaction in post-surgical patients, but since the solubility of dabigatran etexilate is highly dependent upon an acidic gastric environment, it is suspected that antacids decrease the absorption (and consequently, the bioavailability and exposure) of dabigatran by decreasing the solubility of the parent dabigatran etexilate in the gastrointestinal tract.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Pradaxa (dabigatran etexilate). Burlington, Ontario: Boehringer Ingelheim Canada Ltd., September 2012.</p>\n<p>2. Prescribing information. Pradax (dabigatran etexilate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., January 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4434":"<p><b>Title</b> Dabigatran Etexilate / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients closely for decreased anticoagulant effects of dabigatran when concomitantly administered with a proton pump inhibitor.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> Dabigatran AUC and maximum concentration (Cmax) were an average of 32% and 40% lower, respectively, when dabigatran (150 mg x1) was given after pretreatment with pantoprazole (40 mg twice/day starting 2 days prior) in a study of 18 healthy volunteers.<sup>1</sup> Similarly, dabigatran AUC and Cmax were an average of 18-19% and 20-23% lower, respectively, with concurrent pantoprazole (40 mg twice/day) in a study of 36 healthy elderly volunteers who were randomly assigned to pantoprazole or no pantoprazole to be started 2 days prior to dabigatran (150 mg twice/day x 6 days).<sup>2</sup> Tests of the pharmacodynamic response to dabigatran (ECT and aPTT) did not reveal any overall significant differences in dabigatran effects, despite the modest pharmacokinetic impact of pantoprazole; although, decreased steady state aPTT and/or ECT were observed in selected cases.<br><br>Of note, a large clinical trial comparing dabigatran to warfarin in more than 18,000 patients, 13.5-13.9% of whom were also being treated with a proton pump inhibitor, failed to detect any evidence of significant interaction.<sup>3</sup><br><br>The Canadian product monograph for dabigatran etexilate (prodrug) does caution that concomitant administration of pantoprazole resulted in an approximate 30% reduction in dabigatran (active drug) AUC and that decreased clinical effects may occur.<sup>4</sup> However, no dose adjustment is recommended. The U.S. prescribing information for dabigatran does not discuss this interaction at all, only noting that dabigatran does not alter the pharmacokinetics of pantoprazole.<sup>5</sup><br><br>The precise mechanism for this possible interaction is uncertain, though available data suggest dabigatran absorption is increased with lower gastric pH, and that increased gastric pH may modestly decrease absorption/bioavailability.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stangier J, Eriksson BI, Dahl O, et al, “Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement,” <i>J Clin Pharmacol</i>, 2005, 45:555-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15831779\">[PubMed 15831779]</a></p>\n<p>2. Stangier J, Stahle H, Rathgen K, et al, “Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects,” <i>Clin Pharmacokinet</i>, 2008, 47(1):47-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18076218\">[PubMed 18076218]</a></p>\n<p>3. Connolly SJ, Ezekowitz MD, Yusuf S, et al, “Dabigatran Versus Warfarin in Patients with Atrial Fibrillation,” <i>N Engl J Med</i>, 2009, 361(12):1139-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19717844\">[PubMed 19717844]</a></p>\n<p>4. Product monograph. Pradax (dabigatran etexilate). Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd., June 2008.</p>\n<p>5. Prescribing information. Pradaxa (dabigatran etexilate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 10/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4435":"<p><b>Title</b> Dabigatran Etexilate / QuiNIDine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Specific recommendations for management of this interaction may be different for those receiving dabigatran for prophylaxis following orthopedic surgery vs. those with atrial fibrillation receiving prophylaxis vs. those being treated for deep venous thrombosis or pulmonary embolism.</p></li>\n <li><p><b>International labeling</b>: Recommendations in the Canadian labeling regarding the management of this interaction are somewhat different from those in the U.S. labeling.</p></li>\n <li><p><b>Renal Function</b>: The clinical significance and recommended management of this interaction both increase considerably in patients with moderate (CrCl 30-50 mL/min) or severe (CrCl 15-30 mL/min) renal dysfunction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> QuiNIDine may increase the serum concentration of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The recommendations for management of this potential drug interaction depend on the indication for dabigatran use, patient renal function, and country specific labeling recommendations. <br><br>This combination should be used with caution, and patients receiving dabigatran with concurrent quinidine should be monitored more closely for evidence of bleeding.<br><br>The U.S. prescribing information does not recommend avoiding the combination of quinidine and dabigatran in patients with normal renal function. In patients using dabigatran for the treatment of deep venous thrombosis (DVT) or pulmonary embolism (PE) with moderate renal dysfunction (CrCl 30-50 mL/min), the U.S. prescribing information recommends avoiding the combination of dabigatran and any P-glycoprotein inhibitor (such as quinidine). For the treatment of atrial fibrillation, no dose adjustment is recommended if CrCl is greater than 30 mL/min, but the combination of dabigatran and any P-glycoprotein inhibitor (such as quinidine) should be avoided if renal impairment is severe (CrCl 15-30 mL/min).<br><br>The Canadian product monograph recommends reducing dabigatran etexilate dose to 150 mg/day if concomitantly administered with quinidine, regardless of renal function, for patients using dabigatran for the prevention of venous thromboembolism (VTE) after knee or hip replacement surgery. In patients receiving dabigatran for atrial fibrillation, the Canadian monograph suggests dosing 2 hours prior to quinidine if possible but does not recommend dose adjustment.</p> \n<p><b>Discussion</b> Dabigatran labeling notes that concomitant administration with quinidine (given as a 200 mg dose every 2 hours up to a total dose of 1000 mg) resulted in an increase in dabigatran AUC and maximum serum concentration (C<sub>max</sub>) by 53% and 56%, respectively.<sup>1,2</sup> Due to the risk for an associated increase in drug effects (e.g., bleeding) with the potential increase in dabigatran exposure, the Canadian product monograph recommends a dose reduction of dabigatran etexilate (to 150 mg/day) for the prevention of VTE after knee or hip replacement surgery and to administer dabigatran 2 hours prior to quinidine in the treatment of atrial fibrillation.<sup>2</sup> <br><br>According to U.S. labeling, avoidance of the combination of quinidine and dabigatran may be necessary depending on dabigatran indication and patient renal function. In the treatment of DVT or PE, the combination of dabigatran and quinidine should be avoided if CrCl is less than 50 mL/min. In the treatment of atrial fibrillation, the combination of quinidine and dabigatran should be avoided if renal dysfunction is severe (CrCl 15-30 mL/min).<sup>1</sup><br><br>Dabigatran labeling notes that the prodrug (dabigatran etexilate) is a substrate with moderate affinity for the P-gp transport system, suggesting that the mechanism for these observed interactions is inhibition of P-gp resulting in increased dabigatran concentrations.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Pradaxa</i> (dabigatran etexilate). [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; April 2014.</p>\n<p>2. <i>Pradax</i> (dabigatran etexilate). [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd.; May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4436":"<p><b>Title</b> Dabigatran Etexilate / Amiodarone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Specific recommendations for management of this interaction may be different for those receiving dabigatran for prophylaxis following orthopedic surgery vs. those with atrial fibrillation receiving prophylaxis vs. those being treated for deep venous thrombosis or pulmonary embolism.</p></li>\n <li><p><b>International labeling</b>: Recommendations in the Canadian labeling regarding the management of this interaction are somewhat different from those in the U.S. labeling.</p></li>\n <li><p><b>Renal Function</b>: The clinical significance and recommended management of this interaction both increase considerably in patients with moderate (CrCl 30-50 mL/min) or severe (CrCl 15-30 mL/min) renal dysfunction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The recommendations for management of this potential drug interaction depend on the indication for dabigatran use, patient renal function, and country-specific labeling.<br><br>The U.S. prescribing information does not recommend avoiding the combination of amiodarone and dabigatran in patients with normal renal function. In patients with moderate renal dysfunction (CrCl less than 50 mL/min), the U.S. prescribing information recommends avoiding the combination of dabigatran and any P-glycoprotein inhibitor (such as amiodarone) when dabigatran is being used for the treatment of deep venous thrombosis (DVT) or pulmonary embolism (PE). When dabigatran is used for the treatment of atrial fibrillation, no dose adjustment is recommended if CrCl is greater than 30 mL/min, but the combination of dabigatran and any P-glycoprotein inhibitor (such as amiodarone) should be avoided if renal impairment is severe (CrCl 15-30 mL/min). At least one non-US label recommends reducing the dabigatran dose to 150 mg/day if concomitantly administered with amiodarone, regardless of renal function, for patients using dabigatran for the prevention of venous thromboembolism (VTE) after knee or hip replacement surgery. No such dose adjustment is recommended when dabigatran is used in atrial fibrillation. Closely monitor for increased levels/anticoagulant (bleeding) effects of dabigatran.</p> \n<p><b>Discussion</b> The use of amiodarone was associated with a 1.37-fold increase in incidence rate ratio for major bleeding according a large retrospective cohort study of 91,330 Taiwanese patients with non-valvular atrial fibrillation who were treated with a non-vitamin K antagonist oral anticoagulant (ie, dabigatran, rivaroxaban, or apixaban).<sup>1</sup> Concurrent amiodarone was associated with an increase of 13.9 major bleeding episodes per 1000 person-years. Of note, several other examined combinations in this cohort study yielded findings contrary to what would be expected based on available pharmacokinetic interaction data or known pharmacology of the drugs in question. The precise clinical meaning of these findings is unclear. Dabigatran labeling notes that concomitant use of amiodarone resulted in an average 58% increase in dabigatran (active drug) AUC and a 50% increase in dabigatran maximum concentration.<sup>2,3</sup> Amiodarone has also been reported to increase the renal clearance of dabigatran.<sup>2</sup> Due to the risk for an associated increase in drug effects (eg, bleeding) with the potential increase in dabigatran exposure, a dose reduction of dabigatran (to 150 mg/day) for the prevention of VTE after knee or hip replacement surgery may be necessary. Such a dose reduction is recommended in the Canadian product monograph.<sup>3</sup> According to U.S. labeling, avoidance of the combination of dabigatran and amiodarone may be necessary depending on the dabigatran indication and patient renal function.<sup>2</sup> In the treatment of DVT or PE, the combination of dabigatran and any P-gp inhibitor (such as amiodarone) should be avoided if CrCl is less than 50 mL/min. In the treatment of atrial fibrillation, the combination of dabigatran and any P-gp inhibitor (such as amiodarone) should be avoided if renal function is severe (CrCl 15-30 mL/min).<sup>2</sup><br><br>Dabigatran labeling notes that the prodrug (dabigatran etexilate) is a substrate with moderate affinity for the P-gp transport system, suggesting that the mechanism for these observed interactions is inhibition of P-gp resulting in increased dabigatran concentrations.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28973247\">[PubMed 28973247]</a></p>\n<p>2. Pradaxa (dabigatran etexilate). [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; November 2015.</p>\n<p>3. Pradaxa (dabigatran etexilate). [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd.; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4439":"<p><b>Title</b> Dabigatran Etexilate / AtorvaSTATin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> AtorvaSTATin may decrease the serum concentration of Dabigatran Etexilate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for decreased levels/effects of dabigatran if used concomitantly with atorvastatin.</p> \n<p><b>Discussion</b> According to a large retrospective cohort study of 91,330 Taiwanese patients with non-valvular atrial fibrillation who were treated with dabigatran (49.65% of participants) or another non-vitamin K antagonist oral anticoagulant (ie, rivaroxaban or apixaban), concurrent use of atorvastatin was associated with a 29% decrease in the incidence rate ratio for major bleeding.<sup>1</sup> Several other examined combinations in this cohort study yielded findings contrary to what would be expected based on available pharmacokinetic interaction data or known pharmacology of the drugs in question. The precise clinical meaning of these findings is unclear.<br><br>Dabigatran etexilate Canadian product monograph notes that concomitant use with atorvastatin was associated with an approximate 20% reduction in dabigatran (active drug) concentrations.<sup>2</sup> Dosage adjustment of either agent is not recommended. The mechanism behind this apparent interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28973247\">[PubMed 28973247]</a></p>\n<p>2. Pradaxa (dabigatran etexilate). [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd.; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4440":"<p><b>Title</b> Milrinone / Anagrelide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anagrelide may enhance the adverse/toxic effect of Milrinone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of anagrelide and milrinone.</p> \n<p><b>Discussion</b> Both milrinone and anagrelide are capable of inhibiting cyclic AMP phosphodiesterase III, so their combined use may result in additive or synergistic effects. Specific clinical data regarding this possible interaction are lacking, so this interaction potential remains theoretical at present, but anagrelide prescribing information states that their combined use should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Agrylin (anagrelide) [prescribing information]. Wayne, PA: Shire US Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4441":"<p><b>Title</b> Cilostazol / Anagrelide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anagrelide may enhance the adverse/toxic effect of Cilostazol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of anagrelide and cilostazol.</p> \n<p><b>Discussion</b> Both cilostazol and anagrelide are capable of inhibiting cyclic AMP phosphodiesterase III, so their combined use may result in additive or synergistic effects. Specific clinical data regarding this possible interaction are lacking, so this interaction potential remains theoretical at present, but anagrelide prescribing information states that their combined use should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Agrylin (anagrelide) [prescribing information]. Wayne, PA: Shire US Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4442":"<p><b>Title</b> Amphetamines / Gastrointestinal Acidifying Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Gastrointestinal Acidifying Agents may decrease the serum concentration of Amphetamines. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to amphetamines when used together with gastrointestinal acidifying agents as reduced absorption of amphetamines may result, possibly leading to decreased concentration and diminished clinical response.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n <p><b>Gastrointestinal Acidifying Agents Interacting Members</b> Ascorbic Acid, Glutamic Acid, Reserpine</p>\n</div> \n<p><b>Discussion</b> Prescribing information for various amphetamine-containing products caution that gastrointestinal acidifying agents may reduce the absorption of amphetamines.<sup>1,2</sup> The suspected mechanism of this interaction is increased ionization of the amphetamine molecule in the more acidic gastrointestinal environment, leading to impaired absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Adderall (dextroamphetamine and amphetamine). Wayne, PA: Shire US Inc., 3/07.</p>\n<p>2. Prescribing information. Dexedrine (dextroamphetamine). Research Triangle Park, NC: GlaxoSmithKline, July 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4443":"<p><b>Title</b> Amphetamines / Methenamine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methenamine may decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to amphetamines when used together with methenamine or other urine acidifying agents as enhanced excretion of amphetamines may result, possibly leading to decreased concentrations and diminished clinical response.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> Hippuric acid, an essential component of methenamine therapy, is used to maintain an acidic urinary pH, and the pH-dependent renal excretion of amphetamines has been repeatedly demonstrated. Acidification of the urine (with ammonium chloride, dosed to pH = 5.3) was shown in one study to increase renal excretion of (+)-amphetamine to 59.0-83.5% of a dose within 24 hours from an average of 32.9% (12-44%) with unregulated urinary pH.<sup>1</sup> In another study, acidification of the urine resulted in more than a 3-fold increase in mean 16-hour excretion of amphetamine compared to that excreted in 16 hours with uncontrolled urinary pH (mean 54.5% vs. 14.5%, respectively; n=6).<sup>2</sup> Acidification of the urine has also been shown to reduce amphetamine plasma concentrations,<sup>3</sup> shorten the elimination half-life,<sup>4</sup> and increase urinary excretion rate.<sup>3</sup><br><br>Studies with amphetamine derivatives (e.g., ephedrine, methylamphetamine, etc.) have generally shown this same pH-dependent renal excretion of unchanged drug,<sup>5</sup> with observations that increasing methylation of the amino group increases this pH-dependence.<sup>5</sup><br><br>The ability to hasten amphetamine removal via acidification has also generated interest in using this to treat cases of amphetamine overdose or toxicity, with studies demonstrating the utility of strategy for both amphetamine<sup>6</sup> and methamphetamine<sup>7</sup> overdoses.<br><br>The most simple mechanism of this interaction that has been proposed is that the basic amphetamine molecule becomes ionized in the acidic filtrate, preventing any renal tubular reabsorption and enhancing urinary elimination. An alternative mechanism has also been proposed after a pharmacokinetic study demonstrated that preventing tubular reabsorption alone would not be able to account for the substantial impact of acidification on plasma amphetamine concentrations and urinary excretion rates.<sup>3</sup> Under this proposed alternative mechanism, diffusion of parent drug directly into the filtrate occurs as a result of the tremendous concentration gradient for unchanged drug between plasma and filtrate (where virtually all amphetamine present is in its ionized form), resulting in enhanced elimination (beyond simply filtered drug becoming ionized and trapped in filtrate/urine) and reduced plasma concentrations.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Beckett AH, Rowland M, “Urinary Excretion Kinetics of Amphetamine in Man,” <i>J Pharm Pharmacol</i>, 1965, 17(10):628-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4379686\">[PubMed 4379686]</a> </p>\n<p>2. Beckett AH, Rowland M, Turner P, “Influence of Urinary pH on Excretion of Amphetamine,” <i>Lancet</i>, 1965, 1:303. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14247879\">[PubMed 14247879]</a> </p>\n<p>3. Beckett AH, Salmon JA, Mitchard M, “The Relation Between Blood Levels and Urinary Excretion of Amphetamine Under Controlled Acidic and Under Fluctuating Urinary pH Values Using [14C] Amphetamine,” <i>J Pharm Pharmacol</i>, 1969, 21(4):251-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4390145\">[PubMed 4390145]</a> </p>\n<p>4. Davis JM, Kopin IJ, Lemberger L, et al, “Effects of Urinary pH on Amphetamine Metabolism,” <i>Ann NY Acad Sci</i>, 1971, 179:493-501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5285389\">[PubMed 5285389]</a> </p>\n<p>5. Wilkinson GR, Beckett AH, “Absorption Metabolism and Excretion of the Ephedrines in Man. I. The Influence of Urinary pH and Urine Volume Output,” <i>J Pharmacol Exp Ther</i>, 1968, 162(1):139-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5656593\">[PubMed 5656593]</a> </p>\n<p>6. Anggard E, Jonsson LE, Hogmark AL, et al, “Amphetamine Metabolism in Amphetamine Psychosis,” <i>Clin Pharmacol Ther</i>, 1973, 14(5):870-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4729903\">[PubMed 4729903]</a> </p>\n<p>7. Gary NE, Saidi P, “Methamphetamine Intoxication. A Speedy New Treatment,” <i>Am J Med</i>, 1978, 64(3):537-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=637062\">[PubMed 637062]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4444":"<p><b>Title</b> Antihistamines / Amphetamines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amphetamines may diminish the sedative effect of Antihistamines. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Note that amphetamines may negate the sedative effects of antihistamines. When these sedative effects are clinically desirable, monitoring of response to antihistamines will be necessary. When antihistamine-associated sedation is undesireable, no change to antihistamine therapy should be required.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n <p><b>Antihistamines Interacting Members</b> Acrivastine, Bilastine, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, Clemastine, Cyclizine, Cyproheptadine, Desloratadine, Dexbrompheniramine, Dexchlorpheniramine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Doxylamine, Ebastine, Emedastine (Systemic), Fexofenadine, HydrOXYzine, Ketotifen (Systemic), Levocetirizine, Loratadine, Meclizine, Mequitazine, Olopatadine (Systemic), Oxatomide, Oxomemazine, Pheniramine, Phenyltoloxamine, Pizotifen, Pyrilamine (Systemic), Rupatadine, Thonzylamine, Trimeprazine, Triprolidine</p>\n</div> \n<p><b>Discussion</b> Prescribing information for multiple amphetamine products caution that amphetamines may negate the sedative effects of various antihistamines.<sup>1,2</sup> The likely mechanism of this interaction is a direct antagonism of antihistamine-mediated sedation by the stimulatory effects of amphetamines.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Adderall (dextroamphetamine and amphetamine). Wayne, PA: Shire US Inc., 3/07.</p>\n<p>2. Prescribing information. Dexedrine (dextroamphetamine). Research Triangle Park, NC: GlaxoSmithKline, July 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4445":"<p><b>Title</b> Warfarin / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Darunavir may decrease the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor INR and clinical response to warfarin therapy closely when using darunavir and warfarin in combination, and particularly with darunavir initiation/discontinuation or dose adjustments.</p> \n<p><b>Discussion</b> Darunavir prescribing information cautions that darunavir may decrease warfarin concentrations and recommends increased monitoring of warfarin (i.e., INR) during concurrent therapy.<sup>1</sup> The specific mechanism of this potential interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Prezista (darunavir). Raritan, NJ: Tibotec Therapeutics, June 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4446":"<p><b>Title</b> PARoxetine / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Darunavir may decrease the serum concentration of PARoxetine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to paroxetine therapy closely, and watch particularly for signs of decreased response, when paroxetine is used together with darunavir/ritonavir.</p> \n<p><b>Discussion</b> Average paroxetine (20mg daily) AUC was decreased 39% when administered together with darunavir/ritonavir (400mg/100mg BID) in a study (n=16) described in darunavir prescribing information.<sup>1</sup> Paroxetine maximum and minimum concentrations were similarly decreased. The mechanism of this apparent interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Prezista (darunavir). Raritan, NJ: Tibotec Therapeutics, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4447":"<p><b>Title</b> Sertraline / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Darunavir may decrease the serum concentration of Sertraline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased sertraline efficacy if combined with darunavir/ritonavir. The effects of darunavir/cobicistat on sertraline exposure are unknown, but monitoring for increased or decreased sertraline effects is recommended.</p> \n<p><b>Discussion</b> Average sertraline (50mg daily) AUC was decreased 49% when administered together with darunavir/ritonavir (400mg/100mg BID) in a study (n=13) described in the darunavir prescribing information.<sup>1</sup> Sertraline maximum and minimum concentrations were similarly decreased. The effect of darunavir/cobicistat on sertraline pharmacokinetics is unknown, but <br>the product labeling for darunavir/cobicistat recommends using the lowest feasible initial or maintenance dose of sertraline and careful titration to desired effect when this combination is used.<sup>2</sup> <br><br>The mechanism of this apparent interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prezista (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP; June 2016.</p>\n<p>2. Prezcobix (darunavir and cobicistat) [prescribing information]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4448":"<p><b>Title</b> Zoster Vaccine (Live/Attenuated) / Acyclovir-Valacyclovir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Acyclovir-Valacyclovir may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When possible, discontinue antiviral agents with activity against zoster viruses (i.e., acyclovir, valacyclovir, famciclovir) at least 24 hours prior to receiving a live attenuated zoster vaccine. Also, avoid starting such antiviral agents until at least 14 days after vaccination.</p>\n<div>\n <p><b>Acyclovir-Valacyclovir Interacting Members</b> Acyclovir (Systemic), ValACYclovir</p>\n</div> \n<p><b>Discussion</b> Though specific studies evaluating concurrent use of acyclovir or valacyclovir with live attenuated zoster vaccine have not been performed,<sup>1</sup> CDC recommendations state that antiviral agents with activity against zoster viruses (i.e., acyclovir, valacyclovir, famciclovir) should be discontinued at least 24 hours prior to receiving a live attenuated zoster vaccine.<sup>2</sup> Additionally, such antiviral agents should not be used for at least 14 days after vaccination, in order to allow the attenuated vaccine virus adequate time for replication.<sup>2</sup><br><br>The rationale for these recommendations is that selected antiviral agents may interfere with the replication of the virus contained within the vaccine, limiting its effectiveness.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zostavax</i> (zoster vaccine live) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; June 2008.</p>\n<p>2. Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule, United States - 2015. http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule-bw.pdf (accessed 29 April 2015).</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4449":"<p><b>Title</b> Zoster Vaccine (Live/Attenuated) / Famciclovir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Famciclovir may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When possible, discontinue antiviral agents with activity against zoster viruses (i.e., acyclovir, valacyclovir, famciclovir) at least 24 hours prior to receiving a live attenuated zoster vaccine. Also, avoid starting such antiviral agents until at least 14 days after vaccination.</p> \n<p><b>Discussion</b> Though specific studies evaluating concurrent use of famciclovir with live attenuated zoster vaccine have not been performed,<sup>1</sup> CDC recommendations state that antiviral agents with activity against zoster viruses (i.e., acyclovir, valacyclovir, famciclovir) should be discontinued at least 24 hours prior to receiving a live attenuated zoster vaccine.<sup>2</sup> Additionally, such antiviral agents should not be used for at least 14 days after vaccination, in order to allow the attenuated vaccine virus adequate time for replication.<sup>2</sup><br><br>The rationale for these recommendations is that selected antiviral agents may interfere with the replication of the virus contained within the vaccine, limiting its effectiveness.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zostavax (zoster vaccine live). Whitehouse Station, NJ: Merck &amp; Co., Inc., June 2008.</p>\n<p>2. Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule, United States - 2015. http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule-bw.pdf (accessed 29 April 2015).</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4450":"<p><b>Title</b> Caspofungin / Inducers of Drug Clearance</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Inducers of Drug Clearance may decrease the serum concentration of Caspofungin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Caspofungin prescribing information recommends considering use of an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance. Monitor for reduced effects of caspofungin during concurrent therapy.</p>\n<div>\n <p><b>Inducers of Drug Clearance Interacting Members</b> CarBAMazepine, Dexamethasone (Systemic), Efavirenz, Nevirapine, Phenytoin, RifAMPin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Studies with rifampin show up to a 30% reduction in caspofungin minimum concentration when caspofungin is used in subjects receiving rifampin for 28 days.<sup>1</sup> The suspected mechanism of this interaction is rifampin-mediated induction of caspofungin clearance via induction of the OATP1B1 uptake transporter (and/or other transport proteins).<sup>2</sup> It is suspected that other non-specific inducers of drug clearance could interact with caspofungin in a similar manner, and as a result, caspofungin prescribing information recommends considering use of an increased caspofungin dose when coadministered with known inducers of drug clearance (rifampin, nevirapine, efavirenz, carbamazepine, dexamethasone, and phenytoin are specifically listed in the prescribing information).<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. <i>Antimicrob Agents Chemother</i>. 2004;48(11):4306-4314. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15504857\">[PubMed 15504857]</a></p>\n<p>2. Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. <i>Drug Metab Dispos</i>. 2005;33(5):676-682. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15716364\">[PubMed 15716364]</a></p>\n<p>3. Cancidas (caspofungin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4451":"<p><b>Title</b> Alfuzosin / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of alfuzosin with a strong CYP3A4 inhibitor is a listed contraindication according to alfuzosin prescribing information.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Alfuzosin AUC and maximum plasma concentration (Cmax) were increased 3.2- and 2.3-fold, respectively, following administration (single 10 mg alfuzosin dose) with the strong CYP3A4 inhibitor ketoconazole (400 mg daily).<sup>1</sup> A study with diltiazem (240 mg/day), a more moderate CYP3A4 inhibitor, showed a less substantial interaction, with an 1.3-fold increase in alfuzosin AUC and a 1.5-fold increase in alfuzosin Cmax.<sup>1</sup><br><br>As alfuzosin is metabolized by CYP3A4, the presumed mechanism of this interaction is decreased alfuzosin metabolism by strong CYP3A4 inhibitors such as ketoconazole, leading to increased alfuzosin concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Uroxatral (alfuzosin). Bidgewater, NJ: Sanofi-Aventis U.S. LLC, April 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4453":"<p><b>Title</b> Cisapride / Amitriptyline</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Amitriptyline may enhance the arrhythmogenic effect of Cisapride. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of amitriptyline with cisapride is contraindicated.</p> \n<p><b>Discussion</b> Amitriptyline prescribing information states that concurrent use with cisapride is contraindicated due to the risk of QT-interval prolongation and the increased possibility of pro-arrhythmia effects.<sup>1</sup> The specific mechanism of this interaction is unclear, but each agent has been independently associated with QT-prolonging effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Elavil (amitriptyline). Wilmington, DE: Zeneca Pharmaceuticals, 12/00.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4455":"<p><b>Title</b> Colistimethate / Polymyxin B</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the risk for excessive neuromuscular blockade, use caution when using colistimethate together with other drugs capable of causing neuromuscular blockade (such as polymyxin B), and monitor patients closely.</p> \n<p><b>Discussion</b> Several case reports and studies describe neuromuscular blockade (respiratory muscle paralysis) associated with polymyxin antibiotics [e.g., colistimethate (polymyxin E), polymyxin B] with or without concomitant use of neuromuscular-blocking agents.<sup>1,2,3,4,5,6,7,8,9</sup> Calcium gluconate was effectively employed in reversing the blockade in one patient.<sup>2</sup> The polymyxins appear to possess independent neuromuscular-blocking characteristics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pittinger CB, Eryasa Y, and Adamson R, “Antibiotic-Induced Paralysis,” <i>Anesth Analg</i>, 1970, 49:487. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4102601\">[PubMed 4102601]</a> </p>\n<p>2. Giala MM and Paradelis AG, “Two Cases of Prolonged Respiratory Depression Due to Interaction of Pancuronium With Colistin and Streptomycin,” <i>J Antimicrob Chemother</i>, 1979, 5:234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=429254\">[PubMed 429254]</a> </p>\n<p>3. Fogdall RP and Miller RD, “Prolongation of Pancuronium-Induced Neuromuscular Blockade by Polymyxin B,” <i>Anesthesiology</i>, 1974, 40(1): 84-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4359101\">[PubMed 4359101]</a> </p>\n<p>4. Small GA, “Respiratory Paralysis After a Large Dose of Intraperitoneal Polymyxin B and Bacitracin,” <i>Anesth Analg</i>, 1964, 43:137-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14164930\">[PubMed 14164930]</a> </p>\n<p>5. Pohlmann G, “Respiratory Arrest Associated With Intravenous Administration of Polymyxin B Sulfate,” <i>JAMA</i>, 1966, 196:181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4286165\">[PubMed 4286165]</a> </p>\n<p>6. Singh YN, Marshall IG, Harvey AL, “Pre- and Postjunctional Blocking Effects of Aminoglycoside, Polymyxin, Tetracycline and Lincosamide Antibiotics,” <i>Br J Anaesth</i>, 1982, 54(12):1295-306. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6293521\">[PubMed 6293521]</a> </p>\n<p>7. Fiekers JF, “Neuromuscular Block Produced by Polymyxin B: Interaction with End-Plate Channels,” <i>Eur J Pharmacol</i>, 1981, 70(1):77-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6260516\">[PubMed 6260516]</a> </p>\n<p>8. Durant NN, Lambert JJ, “The Action of Polymyxin B at the Frog Neuromuscular Junction,” <i>Br J Pharmacol</i>, 1981, 72(1):41-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6112033\">[PubMed 6112033]</a> </p>\n<p>9. Lee C, de Silva AJ, “Interaction of Neuromuscular Blocking Effects of Neomycin and Polymyxin B,” <i>Anesthesiology</i>, 1979, 50(3):218-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=219730\">[PubMed 219730]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4456":"<p><b>Title</b> Colistimethate / Capreomycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Capreomycin may enhance the neuromuscular-blocking effect of Colistimethate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the risk for excessive neuromuscular blockade, use caution when using capreomycin (particularly at higher doses) together with other drugs capable of causing neuromuscular blockade (such as colistimethate), and monitor patients closely.</p> \n<p><b>Discussion</b> According to capreomycin prescribing information, partial neuromuscular blockade has been noted with large capreomycin doses.<sup>1</sup> Consequently, caution should be used when using capreomycin with other drugs capable of altering neuromuscular function.<br><br>Several case reports describe the occurrence of neuromuscular blockade (respiratory muscle paralysis) during the use of polymyxin antibiotics [e.g., colistimethate (polymyxin E), polymyxin B] with or without concomitant use of neuromuscular-blocking agents.<sup>2,3,4,5,6</sup> Calcium gluconate was effectively employed in reversing the blockade in one patient.<sup>3</sup> The polymyxins appear to possess independent neuromuscular-blocking characteristics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Capastat (capreomycin). Indianapolis, IN: Eli Lilly and Company, January 2008.</p>\n<p>2. Pittinger CB, Eryasa Y, and Adamson R, “Antibiotic-Induced Paralysis,” <i>Anesth Analg</i>, 1970, 49:487.</p>\n<p>3. Giala MM and Paradelis AG, “Two Cases of Prolonged Respiratory Depression Due to Interaction of Pancuronium With Colistin and Streptomycin,” <i>J Antimicrob Chemother</i>, 1979, 5:234.</p>\n<p>4. Fogdall RP and Miller RD, “Prolongation of Pancuronium-Induced Neuromuscular Blockade by Polymyxin B,” <i>Anesthesiology</i>, 1974, 41:407.</p>\n<p>5. Small GA, “Respiratory Paralysis After a Large Dose of Intraperitoneal Polymyxin B and Bacitracin,” <i>Anesth Analg</i>, 1964, 43:137-9.</p>\n<p>6. Pohlmann G, “Respiratory Arrest Associated With Intravenous Administration of Polymyxin B Sulfate,” <i>JAMA</i>, 1966, 196:181.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4457":"<p><b>Title</b> Neuromuscular-Blocking Agents / Capreomycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Capreomycin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the risk for excessive neuromuscular blockade, use caution when using capreomycin (particularly at higher doses) together with any neuromuscular-blocking agents, and monitor patients closely.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine, Vecuronium</p>\n</div> \n<p><b>Discussion</b> According to capreomycin prescribing information, partial neuromuscular blockade has been noted with large capreomycin doses.<sup>1</sup> Consequently, caution should be used when using capreomycin with other drugs capable of altering neuromuscular function.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Capastat (capreomycin). Indianapolis, IN: Eli Lilly and Company, January 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4458":"<p><b>Title</b> Polymyxin B / Capreomycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Capreomycin may enhance the neuromuscular-blocking effect of Polymyxin B. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the risk for excessive neuromuscular blockade, use caution when using capreomycin (particularly at higher doses) together with other drugs capable of causing neuromuscular blockade (such as polymyxin B), and monitor patients closely.</p> \n<p><b>Discussion</b> According to capreomycin prescribing information, partial neuromuscular blockade has been noted with large capreomycin doses.<sup>1</sup> Consequently, caution should be used when using capreomycin with other drugs capable of altering neuromuscular function.<br><br>Several case reports and studies describe neuromuscular blockade (respiratory muscle paralysis) associated with polymyxin antibiotics [e.g., colistimethate (polymyxin E), polymyxin B] with or without concomitant use of neuromuscular-blocking agents.<sup>2,3,4,5,6,7,8,9,10</sup> Calcium gluconate was effectively employed in reversing the blockade in one patient.<sup>3</sup> The polymyxins appear to possess independent neuromuscular-blocking characteristics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Capastat (capreomycin). Indianapolis, IN: Eli Lilly and Company, January 2008.</p>\n<p>2. Pittinger CB, Eryasa Y, and Adamson R, “Antibiotic-Induced Paralysis,” <i>Anesth Analg</i>, 1970, 49:487.</p>\n<p>3. Giala MM and Paradelis AG, “Two Cases of Prolonged Respiratory Depression Due to Interaction of Pancuronium With Colistin and Streptomycin,” <i>J Antimicrob Chemother</i>, 1979, 5:234.</p>\n<p>4. Fogdall RP and Miller RD, “Prolongation of Pancuronium-Induced Neuromuscular Blockade by Polymyxin B,” <i>Anesthesiology</i>, 1974, 41:407.</p>\n<p>5. Small GA, “Respiratory Paralysis After a Large Dose of Intraperitoneal Polymyxin B and Bacitracin,” <i>Anesth Analg</i>, 1964, 43:137-9.</p>\n<p>6. Pohlmann G, “Respiratory Arrest Associated With Intravenous Administration of Polymyxin B Sulfate,” <i>JAMA</i>, 1966, 196:181.</p>\n<p>7. Singh YN, Marshall IG, Harvey AL, “Pre- and Postjunctional Blocking Effects of Aminoglycoside, Polymyxin, Tetracycline and Lincosamide Antibiotics,” <i>Br J Anaesth</i>, 1982, 54(12):1295-306.</p>\n<p>8. Fiekers JF, “Neuromuscular Block Produced by Polymyxin B: Interaction with End-Plate Channels,” <i>Eur J Pharmacol</i>, 1981, 70(1):77-81.</p>\n<p>9. Durant NN, Lambert JJ, “The Action of Polymyxin B at the Frog Neuromuscular Junction,” <i>Br J Pharmacol</i>, 1981, 72(1):41-7.</p>\n<p>10. Lee C, de Silva AJ, “Interaction of Neuromuscular Blocking Effects of Neomycin and Polymyxin B,” <i>Anesthesiology</i>, 1979, 50(3):218-20.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4459":"<p><b>Title</b> Aminoglycosides / Capreomycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Capreomycin may enhance the neuromuscular-blocking effect of Aminoglycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the risk for excessive neuromuscular blockade, use caution when using capreomycin (particularly at higher doses) together with other drugs capable of causing neuromuscular blockade (such as aminoglycoside antibiotics), and monitor patients closely.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> According to capreomycin prescribing information, partial neuromuscular blockade has been noted with large capreomycin doses.<sup>1</sup> Consequently, caution should be used when using capreomycin with other drugs capable of altering neuromuscular function. Additive or synergistic neuromuscular blockade is a possible complication of combined capreomycin and aminoglycoside therapy as both possess an ability to interfere with nerve transmission and normal neuromuscular function.<br><br>Aminoglycosides possess some neuromuscular-blocking activity that varies from one agent to another. When combined with classic neuromuscular-blocking agents, the respiratory depressant effects have been greater and longer.<sup>2,3,4,5,6,7,8</sup> The effects appear to manifest regardless of the route of aminoglycoside administration, including parenteral, oral, intraperitoneal, intraplural, and beneath skin flaps. The mechanism of these interactions is presumably due to an additive and/or synergistic effect on muscular tone. Aminoglycoside-induced neuromuscular-blockade may be dose-related.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Capastat (capreomycin). Indianapolis, IN: Eli Lilly and Company, January 2008.</p>\n<p>2. Warner WA and Sanders E, “Neuromuscular-Blockade Associated With Gentamicin Therapy,” <i>JAMA</i>, 1971, 215(7):1153-4.</p>\n<p>3. Levanen J and Nordman R, “Complete Respiratory Paralysis Caused by a Large Dose of Streptomycin and Its Treatment With Calcium Chloride,” <i>Ann Clin Res</i>, 1975, 7(1):47-9.</p>\n<p>4. Holtzman JL, “Gentamicin and Neuromuscular Blockade,” <i>Ann Intern Med</i>, 1976, 84(1):55-6 (letter).</p>\n<p>5. Warner WA and Sanders E, “Neuromuscular Blockade Associated With Gentamicin Therapy,” <i>JAMA</i>, 1971, 215(7):1153-4.</p>\n<p>6. Boliston TA and Ashman R, “Tobramycin and Neuromuscular Blockade,” <i>Anaesthesia</i>, 1978, 33(6):552.</p>\n<p>7. Jedeikin R, Dolgunski E, Kaplan R, et al, “Prolongation of Neuromuscular-Blocking Effect of Vecuronium by Antibiotics,” <i>Anaesthesia</i>, 1987, 42(8):858-60.</p>\n<p>8. Giala M, Sareyiannis C, Cortsaris N, et al, “Possible Interaction of Pancuronium and Tubocurarine With Oral Neomycin,” <i>Anaesthesia</i>, 1982, 37(7):776.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4460":"<p><b>Title</b> Phenytoin / Capecitabine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Capecitabine may increase the serum concentration of Phenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Phenytoin dose reductions may be necessary when used together with capecitabine. Monitor phenytoin concentrations and response to therapy (both effectiveness and signs/symptoms of toxicity) closely when using this combination.</p> \n<p><b>Discussion</b> Capecitabine is a prodrug of floxuridine, which is partially converted further to fluorouracil in vivo.<sup>1</sup> Case reports have described phenytoin toxicity associated with concurrent use of capecitabine,<sup>2</sup> floxuridine,<sup>3</sup>, fluorouracil,<sup>2,4,5</sup> and tegafur (another fluorouracil prodrug).<sup>6,7</sup> A study in rats supports these reports, citing up to a 70-75% reduction in phenytoin metabolism in rats given fluorouracil or floxuridine.<sup>8</sup><br><br>The mechanism of this interaction appears to be capecitabine (i.e., fluorouracil/floxuridine)-mediated inhibition of phenytoin p-hydroxylation, a process normally dependent on CYP2C9. Though neither floxuridine or fluorouracil appear to have any direct inhibitory effect on CYP2C9 in microsomal studies,<sup>8,9</sup> studies in rats and patients with colorectal cancer have demonstrated decreased CYP2C9 activity (i.e., phenytoin hydroxylation<sup>8</sup> and losartan/E3174 ratio<sup>10</sup>) following treatment with both floxuridine<sup>8</sup> and fluorouracil<sup>8,10</sup> treatment. Of note, the inhibition appears time- and/or dose-dependent with greater inhibition after 3 cycles of fluorouracil (5.3-fold decrease) than after 1 cycle (28% decrease).<sup>10</sup> Studies with the CYP2C9 substrate warfarin further support this mechanism.<sup>11,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xeloda (capecitabine). Nutley, NJ: Roche Pharmaceuticals, April 2006.</p>\n<p>2. Brickell K, Porter D, Thompson P, “Phenytoin Toxicity Due to Fluoropyrimidines (5FU/Capecitabine): Three Case Reports,” <i>Br J Cancer</i>, 2003, 89(4):615-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12915866\">[PubMed 12915866]</a> </p>\n<p>3. Konishi H, Morita K, Minouchi T, et al, “Probable Metabolic Interaction of Doxifluridine with Phenytoin,” <i>Ann Pharmacother</i>, 2002, 36(5):831-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11978162\">[PubMed 11978162]</a> </p>\n<p>4. Gilbar PJ, Brodribb TR, “Phenytoin and Fluorouracil Interaction,” <i>Ann Pharmacother</i>, 2001, 35(11):1367-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11724084\">[PubMed 11724084]</a> </p>\n<p>5. Rosemergy I, Findlay M, “Phenytoin Toxicity as a Result of 5-Fluorouracil Administration,” <i>N Z Med J</i>, 2002, 115(1159):U124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12362168\">[PubMed 12362168]</a> </p>\n<p>6. Tsuda A, Fujiyama J, Miki A, et al, “The First Case of Phenytoin Intoxication Associated with the Concomitant use of Phenytoin and TS-1, a Combination Preparation of Tegafur, Gimeracil, and Oteracil Potassium,” <i>Cancer Chemother Pharmacol</i>, 2008, 62(3):427-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18026730\">[PubMed 18026730]</a> </p>\n<p>7. Wakisaka S, Shimauchi M, Kaji Y, et al, “Acute Phenytoin Intoxication Associated with the Antineoplastic Agent UFT,” <i>Fukuoka Igaku Zasshi</i>, 1990, 81(4):192-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2116374\">[PubMed 2116374]</a> </p>\n<p>8. Konishi H, Yoshimoto T, Morita K, et al, “Depression of Phenytoin Metabolic Capacity by 5-Fluorouracil and Doxifluridine in Rats,” <i>J Pharm Pharmacol</i>, 2003, 55(1):143-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12625878\">[PubMed 12625878]</a> </p>\n<p>9. Park JY, Kim KA, “Inhibitory Effect of 5-Fluorouracil on Human Cytochrome P(450) Isoforms in Human Liver Microsomes,” <i>Eur J Clin Pharmacol</i>, 2003, 59(5-6):407-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12904931\">[PubMed 12904931]</a> </p>\n<p>10. Gunes A, Coskun U, Boruban C, et al, “Inhibitory Effect of 5-Fluorouracil on Cytochrome P450 2C9 Activity in Cancer Patients,” <i>Basic Clin Pharmacol Toxicol</i>, 2006, 98(2):197-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16445595\">[PubMed 16445595]</a> </p>\n<p>11. Davis DA, Fugate SE, “Increasing Warfarin Dosage Reductions Associated with Concurrent Warfarin and Repeated Cycles of 5-Fluorouracil Therapy,” <i>Pharmacotherapy</i>, 2005, 25(3):442-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15843293\">[PubMed 15843293]</a> </p>\n<p>12. Camidge R, Reigner B, Cassidy J, et al, “Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Cancer,” <i>J Clin Oncol</i>, 2005, 23(21):4719-25. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16034047\">[PubMed 16034047]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4462":"<p><b>Title</b> Phenytoin / Floxuridine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Floxuridine may increase the serum concentration of Phenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Phenytoin dose reductions may be necessary when used together with floxuridine. Monitor phenytoin concentrations and response to therapy (both effectiveness and signs/symptoms of toxicity) closely when using this combination.</p> \n<p><b>Discussion</b> Floxuridine is a prodrug of fluorouracil, converted (largely) to fluorouracil in vivo following administration.<sup>1</sup> Several case reports have described phenytoin toxicity associated with concurrent use of floxuridine<sup>2</sup>, fluorouracil<sup>3,4,5</sup> and the fluorouracil prodrugs/analogs capecitabine,<sup>3</sup> and tegafur.<sup>6,7</sup> A study in rats supports these reports, citing up to a 70-75% reduction in phenytoin metabolism in rats given fluorouracil or floxuridine.<sup>8</sup><br><br>The mechanism of this interaction appears to be fluorouracil-mediated inhibition of phenytoin p-hydroxylation, a process normally dependent on CYP2C9. Though neither floxuridine or fluorouracil appear to have any direct inhibitory effect on CYP2C9 in microsomal studies,<sup>8,9</sup> studies in rats and patients with colorectal cancer have demonstrated decreased CYP2C9 activity (i.e., phenytoin hydroxylation<sup>8</sup> and losartan/E3174 ratio<sup>10</sup>) following treatment with both floxuridine<sup>8</sup> and fluorouracil<sup>8,10</sup> treatment. Of note, the inhibition appears time- and/or dose-dependent with greater inhibition after 3 cycles of fluorouracil (5.3-fold decrease) than after 1 cycle (28% decrease).<sup>10</sup> Studies with the CYP2C9 substrate warfarin further support this mechanism.<sup>11,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Floxuridine. Schaumburg, IL: American Pharmaceutical Partners, Inc., June 2002.</p>\n<p>2. Konishi H, Morita K, Minouchi T, et al, “Probable Metabolic Interaction of Doxifluridine with Phenytoin,” <i>Ann Pharmacother</i>, 2002, 36(5):831-4.</p>\n<p>3. Brickell K, Porter D, Thompson P, “Phenytoin Toxicity Due to Fluoropyrimidines (5FU/Capecitabine): Three Case Reports,” <i>Br J Cancer</i>, 2003, 89(4):615-6.</p>\n<p>4. Gilbar PJ, Brodribb TR, “Phenytoin and Fluorouracil Interaction,” <i>Ann Pharmacother</i>, 2001, 35(11):1367-70.</p>\n<p>5. Rosemergy I, Findlay M, “Phenytoin Toxicity as a Result of 5-Fluorouracil Administration,” <i>N Z Med J</i>, 2002, 115(1159):U124.</p>\n<p>6. Tsuda A, Fujiyama J, Miki A, et al, “The First Case of Phenytoin Intoxication Associated with the Concomitant use of Phenytoin and TS-1, a Combination Preparation of Tegafur, Gimeracil, and Oteracil Potassium,” <i>Cancer Chemother Pharmacol</i>, 2008, 62(3):427-32.</p>\n<p>7. Wakisaka S, Shimauchi M, Kaji Y, et al, “Acute Phenytoin Intoxication Associated with the Antineoplastic Agent UFT,” <i>Fukuoka Igaku Zasshi</i>, 1990, 81(4):192-6.</p>\n<p>8. Konishi H, Yoshimoto T, Morita K, et al, “Depression of Phenytoin Metabolic Capacity by 5-Fluorouracil and Doxifluridine in Rats,” <i>J Pharm Pharmacol</i>, 2003, 55(1):143-9.</p>\n<p>9. Park JY, Kim KA, “Inhibitory Effect of 5-Fluorouracil on Human Cytochrome P(450) Isoforms in Human Liver Microsomes,” <i>Eur J Clin Pharmacol</i>, 2003, 59(5-6):407-9.</p>\n<p>10. Gunes A, Coskun U, Boruban C, et al, “Inhibitory Effect of 5-Fluorouracil on Cytochrome P450 2C9 Activity in Cancer Patients,” <i>Basic Clin Pharmacol Toxicol</i>, 2006, 98(2):197-200.</p>\n<p>11. Davis DA, Fugate SE, “Increasing Warfarin Dosage Reductions Associated with Concurrent Warfarin and Repeated Cycles of 5-Fluorouracil Therapy,” <i>Pharmacotherapy</i>, 2005, 25(3):442-7.</p>\n<p>12. Camidge R, Reigner B, Cassidy J, et al, “Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Cancer,” <i>J Clin Oncol</i>, 2005, 23(21):4719-25.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4464":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Maprotiline</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Maprotiline may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid using maprotiline in any patient who is currently using a monoamine oxidase inhibitor as well as in any patient who has used a monoamine oxidase inhibitor within the past 14 days.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Maprotiline prescribing information lists concurrent or recent use of a monoamine oxidase inhibitor (MAOI) as a contraindication, specifying that at least 14 days should separate MAOI discontinuation and initiation of maprotiline.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Maprotiline. Morgantown, WV: Mylan Pharmaceuticals Inc., July 2003.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4465":"<p><b>Title</b> Cisapride / Protriptyline</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Protriptyline may enhance the arrhythmogenic effect of Cisapride. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of protriptyline with cisapride is contraindicated.</p> \n<p><b>Discussion</b> Protriptyline prescribing information states that concurrent use with cisapride is contraindicated due to the risk of QT-interval prologation and the increased possibility of pro-arrhythmia effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Vivactil (protriptyline). East Hanover, NJ: Odyssey Pharmaceuticals, Inc., 10/04.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4466":"<p><b>Title</b> Sertraline / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Disulfiram may enhance the adverse/toxic effect of Sertraline. This is specifically related to sertraline oral concentrate due to its alcohol content (12%). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of sertraline oral concentrate with disulfiram is contraindicated due to the alcohol content (12%) of the oral concentrate.</p> \n<p><b>Discussion</b> The coadministration of alcohol and disulfiram results in an array of symptoms including throbbing in the head and neck, flushing, sweating, nausea, vomiting, chest pain, and breathing difficulties. These effects were first described in 1937 in rubber industry workers handling tetramethylthiuram disulphide.<sup>1</sup> The syndrome was later characterized with disulfiram.<sup>2</sup> Disulfiram inhibits aldehyde dehydrogenase, the enzyme responsible for converting acetaldehyde (the first metabolite of alcohol) into, eventually, water and carbon dioxide. Acetaldehyde accumulation results in the toxic reactions observed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Williams EE, “Effects of Alcohol on Workers With Carbon Disulfide,” <i>JAMA</i>, 1937, 109:1472.</p>\n<p>2. Hald J, Jacobsen E, and Larsen V, “The Sensitizing Effects of tetramethylthiuramdisulfide (Antabuse) to Ethylalcohol,” <i>Acta Pharmacol</i>, 1948, 4:285-96.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4467":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Tetrabenazine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tetrabenazine may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of tetrabenazine with a monoamine oxidase inhibitor is contraindicated.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> According to tetrabenazine prescribing information, concurrent use of monoamine oxidase inhibitors is contraindicated with tetrabenazine.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xenazine (tetrabenazine). Washington, DC: Prestwick Pharmaceuticals, Inc., May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4468":"<p><b>Title</b> Tetrabenazine / Reserpine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Reserpine may enhance the adverse/toxic effect of Tetrabenazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of reserpine with tetrabenazine is contraindicated. Following discontinuation of reserpine, it is recommended that clinicians wait until chorea re-emerges prior to starting tetrabenazine. Additionally, at least 20 days should separate reserpine discontinuation and initiation of tetrabenazine.</p> \n<p><b>Discussion</b> According to tetrabenazine prescribing information, concurrent use of reserpine is contraindicated with tetrabenazine.<sup>1</sup> Reserpine, like tetrabenazine, is a monoamine depletor and inhibitor of vesicular monoamine transport. Due to the long-lasting effects of reserpine, it is recommended that tetrabenazine only be started after a period of at least 20 days following discontinuation of reserpine.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xenazine (tetrabenazine). Washington, DC: Prestwick Pharmaceuticals, Inc., May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4470":"<p><b>Title</b> Tetrabenazine / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving a strong inhibitor of CYP2D6 together with tetrabenazine should not exceed 50mg of tetrabenazine. Also, patients already taking tetrabenazine prior to starting a strong CYP2D6 inhibitor should have their tetrabenazine dose reduced by 50% upon initiation of the strong CYP2D6 inhibitor.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Studies with the strong CYP2D6 inhibitor paroxetine (20mg daily x 10 days) showed that concentrations (i.e., AUC) of the active alpha- and beta-dihydrotetrabenazine (HTBZ) metabolites were increased 3- to 9-fold (single tetrabenazine 50mg dose).<sup>1</sup> The clinical significance of such an increase in active compound exposure is unclear. Tetrabenazine prescribing information states that QTc-prolongation is not worse with strong CYP2D6 inhibitors, but implies some adverse effects, such as depression, may be concentration-dependent since it is recommended that tetrabenazine dose be reduced if worsening or new depression is detected.<sup>1</sup><br><br>CYP2D6 is the primary enzyme responsible for the metabolism of the active alpha- and beta-HTBZ metabolites to O-dealkylated metabolites.<sup>1</sup> Inhibition of this process is thought to be responsible for this observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xenazine (tetrabenazine). Washington, DC: Prestwick Pharmaceuticals, Inc., May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4471":"<p><b>Title</b> Antipsychotic Agents / Tetrabenazine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tetrabenazine may enhance the adverse/toxic effect of Antipsychotic Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased tetrabenazine adverse effects (such as neuroleptic malignant syndrome, extrapyramidal symptoms, and QTc prolongation) when used together with antipsychotics/neuroleptics.</p>\n<div>\n <p><b>Antipsychotic Agents Interacting Members</b> Amisulpride, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Blonanserin, Brexpiprazole, Bromperidol, Cariprazine, ChlorproMAZINE, Clothiapine, CloZAPine, Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Loxapine, Lurasidone, Methotrimeprazine, Molindone, OLANZapine, Paliperidone, Periciazine, Perphenazine, Pimozide, Pipamperone [INT], Pipotiazine, Prochlorperazine, Promazine, QUEtiapine, RisperiDONE, Sulpiride, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> According to tetrabenazine prescribing information, interactions with antipsychotic/neuroleptic drugs were not studied during tetrabenazine development, and patients taking such agents were eliminated from clinical studies.<sup>1</sup> However, considering the known effects of both tetrabenazine (general monoamine depletor) and antipsychotic/neuroleptic agents (generally, dopamine antagonists), adverse effects such as neuroleptic malignant syndrome (NMS), extrapyramidal symptoms, and QTc prolongation may be worsened by the combination.<sup>1</sup> Case reports of NMS attributed to tetrabenazine and antipsychotic/neuroleptic agents have been reported.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xenazine (tetrabenazine). Washington, DC: Prestwick Pharmaceuticals, Inc., May 2008.</p>\n<p>2. Stevens E, Roman A, Houa M, et al, “Severe Hyperthermia During Tetrabenazine Therapy for Tardive Dyskinesia,” <i>Intensive Care Med</i>, 1998, 24(4):369-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9609418\">[PubMed 9609418]</a> </p>\n<p>3. Petzinger GM, Bressman SB, “A Case of Tetrabenazine-Induced Neuroleptic Malignant Syndrome After Prolonged Treatment,” <i>Mov Disord</i>, 1997, 12(2):246-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9087987\">[PubMed 9087987]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4474":"<p><b>Title</b> Digoxin / Acarbose</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acarbose may decrease the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor digoxin concentrations, and clinical response to digoxin, closely following the addition (or discontinuation) of acarbose. Changes to therapy may be necessary.</p> \n<p><b>Discussion</b> Several case reports describe significant reductions in digoxin concentrations following addition of acarbose.<sup>1,2,3</sup> In all cases, discontinuation of acarbose resulted in increased digoxin concentrations toward pre-acarbose concentrations.<br><br>Digoxin AUC and maximum concentration (Cmax) were significantly reduced (vs. digoxin 0.5mg single dose, without acarbose) by both single-dose acarbose (200mg given 30 minutes prior to digoxin 0.5mg) and 3 days of acarbose (100mg TID, given 30 minutes prior to meals) in three phase study.<sup>4</sup> Conversely, an open-label study of 11 healthy volunteers reported a 28% increase in digoxin Cmax, but no other pharmacokinetic changes, with digoxin (0.75mg x1 on day 8) plus acarbose (50mg TID x 12 days) versus digoxin (0.75mg single dose) alone.<sup>5</sup><br><br>The mechanism of this apparent interaction is unclear. Authors of a published case report have hypothesized that an acarbose-related increase in gastrointestinal motility and/or decrease in intestinal digoxin hydrolysis may be responsible.<sup>2</sup> According to acarbose prescribing information, acarbose may alter digoxin bioavailability.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Serrano JS, Jimenez CM, Serrano MI, et al, “A Possible Interaction of Potential Clinical Interest between Digoxin and Acarbose,” <i>Clin Pharmacol Ther</i>, 1996, 60:589-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8941033\">[PubMed 8941033]</a> </p>\n<p>2. Ben-Ami H, Krivoy N, Nagachandran P, et al, “An Interaction between Digoxin and Acarbose,” <i>Diabetes Care</i>, 1999, 22:860-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10332701\">[PubMed 10332701]</a> </p>\n<p>3. Nagai Y, Hayakawa T, Abe T, et al, “Are There Different Effects of Acarbose and Voglibose on Serum Levels of Digoxin in a Diabetic Patient with Congestive Heart Failure?,” <i>Diabetes Care</i>, 2000, 23:1703. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11092296\">[PubMed 11092296]</a> </p>\n<p>4. Miura T, Ueno K, Tanaka K, et al, “Impairment of Absorption of Digoxin by Acarbose,” <i>J Clin Pharmacol</i>, 1998, 38:654-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9702852\">[PubMed 9702852]</a> </p>\n<p>5. Cohen E, Almog S, Staruvin D, et al, “Do Therapeutic Doses of Acarbose Alter the Pharmacokinetics of Digoxin?,” <i>Isr Med Assoc J</i>, 2002, 4:772-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12389338\">[PubMed 12389338]</a> </p>\n<p>6. Prescribing information. Precose (acarbose). West Haven, CT: Bayer Pharmaceuticals Corporation, 11/04.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4475":"<p><b>Title</b> Efavirenz / Darunavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The use of darunavir/cobicistat with efavirenz is not recommended, while additional monitoring is recommended if darunavir/ritonavir is combined with efavirenz.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Darunavir may increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Darunavir. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased concentrations and effects of darunavir and/or increased concentrations and effects of efavirenz when darunavir/ritonavir is combined with efavirenz. The use of darunavir/cobicistat in combination with efavirenz is not recommended.</p> \n<p><b>Discussion</b> Concomitant administration of darunavir/ritonavir (300 mg/100 mg twice daily) with efavirenz (600 mg once daily) resulted in both decreased darunavir AUC (13%), maximum concentration (Cmax) (15%), and minimum concentration (Cmin) (31%) and decreased ritonavir AUC (28%), Cmax (32%), and Cmin (40%) in a study of 12 healthy volunteers.<sup>1</sup> Conversely, the average efavirenz AUC, Cmax, and Cmin increased by 21%, 15%, and 17%, respectively. In another pharmacokinetic study the average darunavir AUC and Cmin were 14% and 57% lower, respectively, when darunavir/ritonavir (900 mg/100 mg once daily) and efavirenz (600 mg once daily) were given concurrently in a study of 12 healthy volunteers.<sup>2</sup> The darunavir half-life also decreased by an average of 44% (8.5 hours vs. 15.3 hours) with concurrent efavirenz, and the average efavirenz half-life was an average of 66% higher with the combination, although efavirenz concentrations were not significantly changed. Of note, despite the reduced darunavir concentrations with concurrent efavirenz, all measured darunavir minimum serum concentrations remained above the 50% effective concentration (EC50) for the wild-type virus, suggesting the interaction is of questionable clinical significance for patients infected with this particular strain of the virus.<sup>2</sup> <br><br>Product labeling for darunavir states that darunavir/ritonavir can be combined with efavirenz without dose adjustment.<sup>3</sup> However, due to a lack of clinical data, product labeling for darunavir/cobicistat and clinical practice guidelines recommend against the use of darunavir/cobicistat and efavirenz due to the risk of reduced concentrations of darunavir and/or cobicistat and subsequent therapeutic failure.<sup>4,5</sup> <br><br>The likely mechanism of this apparent interaction is efavirenz-mediated induction of the CYP3A metabolism of darunavir and ritonavir, resulting in the modestly decreased concentrations of darunavir and ritonavir, together with darunavir/ritonavir-mediated inhibition of the CYP3A metabolism of efavirenz, resulting in the slightly elevated efavirenz concentrations.<sup>1,3,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sekar VJ, De Pauw M, Marien K, Peeters M, Lefebvre E, Hoetelmans RM. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. <i>Antivir Ther</i>. 2007;12(4):509-514. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17668559\">[PubMed 17668559]</a> </p>\n<p>2. Soon GH, Shen P, Yong EL, Pham P, Flexner C, Lee L. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers. <i>Antimicrob Agents Chemother</i>. 2010;54(7):2775-2780. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20385850\">[PubMed 20385850]</a></p>\n<p>3. <i>Prezista</i> (darunavir) [prescribing information]. Titusville NJ: Janssen Therapeutics; March 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir/cobicistat) [prescribing information]. Titusville NJ: Janssen Therapeutics; January 2015.</p>\n<p>5. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Published April 2015. Accessed April 27, 2015. </p>\n<p>6. <i>Sustiva</i> (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4478":"<p><b>Title</b> Mycophenolate / Proton Pump Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: The Myfortic brand formulation (enteric coated mycophenolate sodium) appears to be less sensitive to this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor mycophenolate therapy closely when used concurrently with a proton pump inhibitor (PPI), including increased monitoring of drug concentrations (when available and applicable) and response to therapy. Patients receiving higher PPI doses and/or more potent PPIs may be at greatest risk, and there may be considerable inter-patient variability in magnitude of interaction. According to one study, black patients may be at higher risk for experiencing acute rejection with use of this combination. The enteric coated mycophenolate sodium formulation appears to be less sensitive to this interaction than mycophenolate mofetil and may be an alternative to consider in patients requiring treatment with a PPI.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole*, Omeprazole*, Pantoprazole*, RABEprazole, Revaprazan</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> It is important to note that the apparent interaction between proton pump inhibitors (PPIs) and mycophenolate is highly dependent on the specific mycophenolate product/formulation used, with mycophenolate mofetil (MMF) more sensitive to this interaction than enteric coated mycophenolate sodium (EC-MPS).<br><br>Several studies, including randomized controlled trials, case-control studies, and retrospective analyses, have reported significant 17% to 37% average reductions in mycophenolic acid (MPA) exposure following MMF administration to patients who were being treated with a PPI.<sup>1,2,3,4,5,6,7,8,9</sup> Such reductions have been principally reported with pantoprazole (20 mg to 80 mg daily),<sup>1,2,3,4,5</sup> omeprazole (27 mg to 80 mg daily),<sup>6,7</sup> and lansoprazole (30 mg daily).<sup>8,9</sup> Use of this combination has also been associated with non-significant increases in both acute rejection episodes (7/21 PPI users vs. 1/12 not using a PPI) and transplant vasculopathy (7/21 PPI users vs. 3/12 not using a PPI),<sup>5</sup> as well as with an average 42% increase in inosine monophosphate dehydrogenase (IMPDH) activity (a measure of clinical mycophenolate effectiveness)<sup>2</sup> and an increased rate of mycophenolate drug transition or withdrawal.<sup>6</sup> In another study, an increased risk of biopsy proven acute rejection (BPAR) within the first year after transplant was noted for concomitant use of MMF with a PPI [15% vs. 12% with no PPI use; RR=1.41 (95% CI: 0.88 to 2.23)], but the difference was only significant among black patients [RR=1.93 (1.18 to 3.16)].<sup>10</sup> In contrast, other studies have reported no significant difference in MPA exposure with concomitant MMF and a PPI,<sup>11,12,13</sup> as well as no difference in BPAR or IMPDH activity associated with coadministration of a PPI.<sup>11,14</sup> The MMF prescribing information generally reflects this uncertainty, acknowledging the reported pharmacokinetic changes but stating that the clinical significance of the apparent interaction is unclear, recommending caution with use of this combination.<sup>15</sup><br><br>Most evidence with the EC-MPS formulation confirms the lack of a significant interaction with PPIs, with several studies reporting no significant change in MPA exposure with concomitant use of EC-MPS with a PPI.<sup>3,11,16</sup><br><br>It is uncertain whether some PPIs are less likely to interact with MMF than others. One study that evaluated both lansoprazole- and rabeprazole-treated patients reported a less notable impact with rabeprazole (no difference in MPA AUC<sub>0-12h</sub> and only an average 11% decrease in MPA AUC<sub>0-6h</sub> vs. 25% to 31% reductions with lansoprazole).<sup>8</sup><br><br>The suspected mechanism of this possible interaction is impaired MMF/MPA absorption and/or hydrolysis at the higher gastric pH that is associated with PPI treatment. The results of an in vitro study support this, showing substantially reduced dissolution of MMF at pH values greater than 4.5, while the EC-MPS formulation displayed almost complete dissolution at pH values of 5 to 7.<sup>12</sup> Concurrent administration of MMF with a magnesium-aluminum antacid was also associated with a significant reduction in MPA concentrations, consistent with a pH-dependent interaction,<sup>15</sup> but the EC-MPS formulation displayed a similar or even greater interaction with antacids, raising questions about other contributing mechanisms such as chelation.<sup>17</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. <i>Transplant Proc</i>. 2010;42(10):4243-4246. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21168674\">[PubMed 21168674]</a></p>\n<p>2. Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. <i>Rheumatology (Oxford)</i>. 2010;49(11):2061-2067. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20671023\">[PubMed 20671023]</a></p>\n<p>3. Rupprecht K, Schmidt C, Raspe A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. <i>J Clin Pharmacol</i>. 2009;49(10):1196-1201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19783713\">[PubMed 19783713]</a></p>\n<p>4. Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. <i>Am J Transplant</i>. 2009;9(7):1650-1656. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19519820\">[PubMed 19519820]</a></p>\n<p>5. Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. <i>J Heart Lung Transplant</i>. 2009;28(6):605-611. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19481022\">[PubMed 19481022]</a></p>\n<p>6. Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China. <i>Transplant Proc</i>. 2014;46(5):1362-1365. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24935300\">[PubMed 24935300]</a></p>\n<p>7. David-Neto E, Takaki KM, Agena F, et al. Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. <i>Ther Drug Monit</i>. 2012;34(3):331-336. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22549498\">[PubMed 22549498]</a></p>\n<p>8. Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. <i>Ther Drug Monit</i>. 2008;30(1):46-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18223462\">[PubMed 18223462]</a></p>\n<p>9. Kato R, Ooi K, Ikura-Mori M, et al. Impairment of mycophenolate mofetil absorption by calcium polycarbophil. <i>J Clin Pharmacol</i>. 2002;42(11):1275-1280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12412828\">[PubMed 12412828]</a></p>\n<p>10. Knorr JP, Sjeime M, Braitman LE, Jawa P, Zaki R, Ortiz J. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. <i>Transplantation</i>. 2014;97(5):518-524. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24162246\">[PubMed 24162246]</a></p>\n<p>11. Rissling O, Glander P, Hambach P, et al. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. <i>Br J Clin Pharmacol</i>. 2015; Apr 24 (Epub ahead of print): doi: 10.1111/bcp.12664. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25913040\">[PubMed 25913040]</a></p>\n<p>12. Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. <i>J Clin Pharmacol</i>. 2012;52(8):1265-1272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21903891\">[PubMed 21903891]</a></p>\n<p>13. Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. <i>Ther Drug Monit</i>. 2011;33(1):120-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21192310\">[PubMed 21192310]</a></p>\n<p>14. van Boekel GA, Kerkhofs CH, van de Logt F, Hilbrands LB. Proton pump inhibitors do not increase the risk of acute rejection. <i>Neth J Med</i>. 2014;72(2):86-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24659591\">[PubMed 24659591]</a></p>\n<p>15. CellCept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; September 2013.</p>\n<p>16. Kofler S, Wolf C, Shvets N, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. <i>J Heart Lung Transplant</i>. 2011;30(5):565-571. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21256049\">[PubMed 21256049]</a></p>\n<p>17. Myfortic (mycophenolic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4479":"<p><b>Title</b> Warfarin / Propranolol</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Propranolol may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The mean warfarin AUC and maximum concentration (Cmax) were increased 17% and 24%, respectively, when warfarin (15mg x1) was administered after 3 days of propranolol (80mg BID) as compared to administration without concurrent beta-blocker in a study of 6 healthy volunteers.<sup>1</sup> Coadministration of atenolol (100mg daily) or metoprolol (100mg BID) also resulted in increases in mean warfarin AUC and Cmax but of less magnitude than those observed with propranolol.<sup>1</sup> Similarly, mean warfarin minimum concentration was 6.5-15% higher (vs. the two 14-day warfarin alone periods) following the addition of propranolol (80mg BID x 14 days) to a warfarin regimen designed to maintain a prothrombin time of 3 seconds above control (average dose = 3.2mg, 42-day treatment period; n=6).<sup>2</sup> Of note, pharmacodynamic measures in both studies revealed no evidence of a greater anticoagulant effect accompanying the observed pharmacokinetic changes.<sup>1,2</sup><br><br>The mechanism of this possible pharmacokinetic interaction is unclear. A combination of human and animal data suggest that the interaction is not the result of altered warfarin protein binding or of altered warfarin metabolism.<sup>2</sup> Altered distribution volume of warfarin (possibly decreased hepatic uptake) by concurrent propranolol has been proposed as a possible mechanism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bax ND, Lennard MS, Tucker GT, et al, “The Effect of Beta-Adrenoceptor Antagonists on the Pharmacokinetics and Pharmacodynamics of Warfarin After a Single Dose,” <i>Br J Clin Pharmacol</i>, 1984, 17(5):553-7.</p>\n<p>2. Scott AK, Park BK, Breckenridge AM, “Interaction Between Warfarin and Propranolol,” <i>Br J Clin Pharmacol</i>, 1984, 17(5):559-64.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4480":"<p><b>Title</b> Atovaquone / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ritonavir may decrease the serum concentration of Atovaquone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When possible, avoid concurrent use of ritonavir (including ritonavir-boosted protease inhibitors) with atovaquone. If this combination can not be avoided, monitor patients closely for evidence of decreased atovaquone clinical effectiveness.</p> \n<p><b>Discussion</b> The atovaquone AUC was an average of 46% and 74% lower, respectively, in HIV-positive patients stable on either lopinavir/ritonavir (800 mg/200 mg daily or 400 mg/100 mg twice/day; n=19) or atazanavir/ritonavir (300 mg/100 mg daily; n=19) than in healthy volunteers (n=18) when the groups were given a single dose of atovaquone/proguanil (250 mg/100 mg).<sup>1</sup> Though there were some notable differences between these study groups (HIV-status, HIV-positive patients were significantly older and more likely to be smokers), the magnitude of the observed difference suggests that a significant interaction may be likely. These findings are also consistent with a warning in the ritonavir prescribing information that notes ritonavir may decrease atovaquone concentrations, potentially requiring a change in atovaquone dose.<sup>2</sup><br><br>The specific mechanism for this observed interaction is not clear. Atovaquone is not appreciably metabolized but is eliminated in the bile, via an apparently active process.<sup>3,4</sup> Whether ritonavir (and/or other ritonavir-boosted protease inhibitors) induces this process, alters atovaquone protein binding (more than 99% bound), and/or interacts via another route is uncertain. The authors of this research letter hypothesize that ritonavir may induce the glucuronidation of atovaquone.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. van Luin M, Van der Ende ME, Richter C, et al, “Lower Atovaquone/Proguanil Concentrations in Patients Taking Efavirenz, Lopinavir/Ritonavir or Atazanavir/Ritonavir,” <i>AIDS</i>, 2010, 24(8):1223-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20299957\">[PubMed 20299957]</a></p>\n<p>2. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, March 2012.</p>\n<p>3. Rolan PE, Mercer AJ, Tate E, et al, “Disposition of Atovaquone in Humans,” <i>Antimicrob Agents Chemother</i>, 1997, 41(6):1319-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9174191\">[PubMed 9174191]</a></p>\n<p>4. Prescribing information. Mepron (atovaquone). Research Triangle Park, NC: GlaxoSmithKline, May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4481":"<p><b>Title</b> Dronabinol / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Dronabinol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for signs and symptoms of dronabinol toxicity when using dronabinol together with ritonavir. Dronabinol dose reductions may be necessary.</p> \n<p><b>Discussion</b> According to ritonavir prescribing information, concurrent use of dronabinol with ritonavir has been associated with increased dronabinol concentrations.<sup>1</sup> Though specific data regarding the magnitude and pharmacodynamic impact of the interaction were not provided, ritonavir prescribing information states that dose reductions of dronabinol may be necessary.<sup>1</sup><br><br>The mechanism for this possible interaction is not clear, but considering the cytochrome P450-dependent metabolism of dronabinol (primarily via CYP2C9 and CYP3A4<sup>2</sup>) and the potent inhibitory effects of ritonavir on CYP3A4 and other enzymes,<sup>1</sup> inhibition of dronabinol metabolism by ritonavir is likely to be at least partially responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, 8/2008.</p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, et al, “Cytochrome P450 Enzymes Involved in the Metabolism of Tetrahydrocannabinols and Cannabinol by Human Hepatic Microsomes,” <i>Life Sci</i>, 2007, 80(15):1415-9.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4482":"<p><b>Title</b> Tolterodine / VinBLAStine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> VinBLAStine may increase the serum concentration of Tolterodine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduce tolterodine dosage to 1 mg twice daily (regular release formulation) or 2 mg daily (extended release formulation) and monitor for increased levels/effects of tolterodine with initiation of vinblastine therapy. Conversely, monitor for decreased levels/effects of tolterodine with discontinuation of vinblastine.</p> \n<p><b>Discussion</b> Vinblastine inhibition of CYP3A4 has previously been demonstrated in independent studies of CYP3A4 substrate metabolism including quinidine (Ki 4.7 and 5.9 micromolar) and denitronifedipine (Ki 20 and 44 micromolar). <sup>1,2</sup> Tolterodine is primarily metabolized by CYP2D6, however in patients who are poor CYP2D6 metabolizers tolterodine is metabolized via CYP3A4.<sup>3</sup> <br><br>It might be expected that concomitant use of tolterodine with a CYP3A4 inhibitor such as vinblastine may increase tolterodine levels and possible adverse events (eg, xerostomia, headache, constipation). Tolterodine prescribing information recommends a reduction in tolterodine dosage with concomitant use of vinblastine. Conversely, changes in vinblastine (also a CYP3A4 substrate) levels/effects are not expected as tolterodine exhibits no clinically relevant CYP3A4 inhibitory activity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nielsen TL, Rasmussen BB, Flinois JP, et al, “In Vitro Metabolism of Quinidine: The (3S)-3-Hydroxylation of Quinidine Is a Specific Marker Reaction for Cytochrome P-4503A4 Activity in Human Liver Microsomes,” <i>J Pharm &amp; Exp Ther</i>, 1999. 289(1): 31-37. </p>\n<p>2. Baumhakel M, Kasel D, Rao-Schymanski RA, et al, “Screening for Inhibitory Effects of Antineoplastic Agents on CYP3A4 in Human Liver Microsomes,” <i>Int J Clin Pharmacol Ther</i>, 2001, 39(12): 517-28.</p>\n<p>3. Prescribing information. Detrol (tolterodine). New York, NY: Pfizer, Inc., 02/08.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4483":"<p><b>Title</b> Sodium Phenylacetate / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Sodium Phenylacetate. Specifically, probenecid may inhibit the renal transport of the phenylacetylglutamine metabolite of sodium phenylacetate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of sodium phenylacetate toxicity (e.g., somnolence, fatigue, lightheadedness, etc.) when used in combination with probenecid.</p> \n<p><b>Discussion</b> Though specific data regarding this potential interaction are lacking, the prescribing information for a combination sodium phenylacetate and sodium benzoate product cautions that probenecid, which inhibits the renal excretion of other similar compounds, may inhibit the renal excretion of the phenylacetylglutamine and hippurate derivative products.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ammonul (sodium phenylacetate and sodium benzoate). Scottsdale, AZ: Ucyclyd Pharma, Inc., October 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4484":"<p><b>Title</b> Sodium Benzoate / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Sodium Benzoate. Specifically, probenecid may inhibit the renal transport of the hippuric acid metabolite of sodium benzoate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of sodium benzoate toxicity when used in combination with probenecid.</p> \n<p><b>Discussion</b> Though specific data regarding this potential interaction are lacking, the prescribing information for a combination sodium benzoate and sodium phenylacetate product cautions that probenecid, which inhibits the renal excretion of other similar compounds, may inhibit the renal excretion of the hippurate and phenylacetylglutamine derivative products.<sup>1</sup> Data from rats further support this possibility, showing that probenecid significantly inhibits the renal excretion of p-amino hippurate.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ammonul (sodium phenylacetate and sodium benzoate). Scottsdale, AZ: Ucyclyd Pharma, Inc., October 2005.</p>\n<p>2. Giorgi G, Urso R, Segre G, “Influence of Probenecid on P-Amino Hippurate Kinetics,” <i>Eur J Drug Metab Pharmacokinet</i>, 1991, Spec No 3:108-10.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4485":"<p><b>Title</b> Levothyroxine / Orlistat</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of levothyroxine are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Orlistat may decrease the serum concentration of Levothyroxine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Separate administration of oral levothyroxine and orlistat by a least 4 hours. Monitor patients closely for signs and symptoms of hypothyroidism.</p> \n<p><b>Discussion</b> Signs and symptoms of hypothyroidism (tiredness, lethargy, and cold intolerance) developed within 2 weeks of initiating orlistat therapy in a 46 year old female patient who had been receiving a TSH-suppressing dose of thyroxine (250 mcg daily) for several years.<sup>1</sup> T4 and TSH were also significantly elevated compared to prior tests, including one performed within the month prior to orlistat therapy. Symptoms and laboratory tests returned to pre-orlistat levels within 2 weeks, following both cessation of orlistat and an increase in the thyroxine dose (to 300 mcg daily).<br><br>Prescribing information for both levothyroxine and orlistat similarly caution that orlistat may reduce the absorption (and effectiveness) of levothyroxine, recommending the separation of administration of the two agents.<sup>2,3</sup> Clinicians are advised to monitor patients closely for inadequate responsiveness/signs of hypothyroidism with concomitant use of these two agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Madhava K, Hartley A, “Hypothyroidism in Thyroid Carcinoma Follow-up: Orlistat May Inhibit the Absorption of Thyroxine,” <i>Clin Oncol (R Coll Radiol)</i>, 2005, 17(6):492. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16149295\">[PubMed 16149295]</a></p>\n<p>2. Prescribing information. Synthroid (levothyroxine). North Chicago, IL: Abbott Laboratories, July 2008.</p>\n<p>3. Prescribing information. Xenical (orlistat). South San Francisco, CA: Genentech USA, Inc., May 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4487":"<p><b>Title</b> Rivaroxaban / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (P-glycoprotein Inhibitors (Clinically Relevant)): This combination should be avoided in patients also receiving P-glycoprotein inhibitors.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. For clarithromycin, refer to more specific clarithromycin-rivaroxaban monograph recommendations. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is typically needed when a strong CYP3A4 inhibitor is administered with rivaroxaban. Avoid combining rivaroxaban with a strong CYP3A4 inhibitor in patients also receiving a P-glycoprotein inhibitor. The strong CYP3A4 inhibitors clarithromycin, itraconazole, ketoconazole, ritonavir (and ritonavir-containing combination products), and telaprevir have higher risk interactions with rivaroxaban and are more fully discussed in separate monographs.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> According to a large retrospective cohort study of 91,330 Taiwanese patients with non-valvular atrial fibrillation who were treated with rivaroxaban (59.13% of participants) or another non-vitamin K antagonist oral anticoagulant (ie, apixaban or dabigatran), concurrent use of a strong CYP3A4 inhibitor (ie, itraconazole, ketoconazole, posaconazole, or voriconazole) did not significantly increase the risk for major bleeding, and erythromycin or clarithromycin use was associated with a 40% decrease in the incidence rate ratio for major bleeding.<sup>1</sup> Of note, several other examined combinations in this cohort study yielded findings contrary to what would be expected based on available pharmacokinetic interaction data or known pharmacology of the drugs in question. The precise clinical meaning of these findings is unclear.<br><br>In clinical studies summarized in rivaroxaban US prescribing information, concurrent use of ketoconazole or ritonavir, both strong CYP3A4 inhibitors that inhibit P-glycoprotein (P-gp), increased rivaroxaban AUC by 2.6- and 2.5-fold, respectively.<sup>2</sup> Concurrent use of clarithromycin, another strong CYP3A4 inhibitor that inhibits P-gp, increased rivaroxaban AUC by only 1.5-fold.<sup>2</sup><br><br>Rivaroxaban is a substrate of both CYP3A4 and P-gp, and its elimination is partially renally-dependent.<sup>2</sup> Rivaroxaban US prescribing information states that its use with strong inhibitors of CYP3A4 that also inhibit P-gp should be avoided due to the potential risk for increased rivaroxaban serum concentrations and bleeding.<sup>2</sup> Combined used of rivaroxaban with any such inhibitors is considered contraindicated according to rivaroxaban Canadian labeling.<sup>3</sup> Similar recommendations should be followed for rivaroxaban prescribing in patients receiving a strong inhibitor of CYP3A4 and a separate agent that inhibits P-gp.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28973247\">[PubMed 28973247]</a></p>\n<p>2. Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc.; March 2017.</p>\n<p>3. Xarelto (rivaroxaban) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4492":"<p><b>Title</b> AzaTHIOprine / Sulfamethoxazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulfamethoxazole may enhance the myelosuppressive effect of AzaTHIOprine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor immune function and hematologic status closely in patients receiving azathioprine who are also given sulfamethoxazole.</p> \n<p><b>Discussion</b> Various reports have described excessive leukopenia associated with use of sulfamethoxazole-trimethoprim (SMZ/TMP) in patients receiving azathioprine.<sup>1,2</sup> One report noted that 6 renal transplant recipients who were given both SMZ/TMP and azathioprine experienced neutropenia and thrombocytopenia at a higher incidence and of longer duration than 25 similar patients who received azathioprine without SMZ/TMP.<sup>2</sup> Another report describes a similar severe leukopenia associated with use of trimethoprim together with azathioprine.<sup>3</sup> Of note, an observational study found that patients receiving azathioprine together with SMZ/TMP experienced no more hematologic toxicity than those receiving azathioprine together with another antibiotic.<sup>4</sup><br><br>The mechanism of this purported interaction is enhancement of 6-mercaptopurine (active moiety of azathioprine) bone marrow suppression by the antifolate actions of TMP/SMZ.<sup>2</sup> Case reports and data from cross-sectional and case-report studies support such an interaction, suggesting that SMZ/TMP can cause hematologic toxicity (independent of any combination with azathioprine).<sup>5,6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hulme B, Reeves DS, “Leucopenia Associated with Trimethoprim-Sulphamethoxazole after Renal Transplantation,” <i>Br Med J</i>, 1971, 3:610-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4936539\">[PubMed 4936539]</a></p>\n<p>2. Bradley PP, Warden GD, Maxwell JG, et al, “Neutropenia and Thrombocytopenia in Renal Allograft Recipients Treated with Trimethoprim-Sulfamethoxazole,” <i>Ann Intern Med</i>, 1980, 93:560-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7001973\">[PubMed 7001973]</a></p>\n<p>3. Bailey RR, “Leukopenia Due to a Trimethoprim-Azathioprine Interaction,” <i>N Z Med J</i>, 1984, 97:739. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6595562\">[PubMed 6595562]</a></p>\n<p>4. Hall CL, “Co-Trimoxazole and Azathioprine: A Safe Combination,” <i>Br Med J</i>, 1974, 4:15-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4609544\">[PubMed 4609544]</a></p>\n<p>5. Andres E, Noel E, Maloisel F, “Trimethoprim-Sulfamethoxazole-Induced Life-Threatening Agranulocytosis,” <i>Arch Intern Med</i>, 2003, 163(16):1975-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12963573\">[PubMed 12963573]</a></p>\n<p>6. van der Klauw MM, Goudsmit R, Halie MR, et al, “A Population-Based Case-Cohort Study of Drug-Associated Agranulocytosis,” <i>Arch Intern Med</i>, 1999, 159(4):369-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10030310\">[PubMed 10030310]</a></p>\n<p>7. van der Klauw MM, Wilson JH, Stricker BH, “Drug-Associated Agranulocytosis: 20 Years of Reporting in The Netherlands (1974-1994),” <i>Am J Hematol</i>, 1998, 57(3):206-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9495370\">[PubMed 9495370]</a></p>\n<p>8. Myers MW, Jick H, “Hospitalization for Serious Blood and Skin Disorders Following Co-Trimoxazole,” <i>Br J Clin Pharmacol</i>, 1997, 43(6):649-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9205827\">[PubMed 9205827]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4493":"<p><b>Title</b> AzaTHIOprine / Trimethoprim</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor immune function and hematologic status closely in patients receiving azathioprine who are also given trimethoprim.</p> \n<p><b>Discussion</b> Various reports have described excessive leukopenia associated with use of sulfamethoxazole-trimethoprim (SMZ/TMP) in patients receiving azathioprine.<sup>1,2</sup> One report noted that 6 renal transplant recipients who were given both SMZ/TMP and azathioprine experienced neutropenia and thrombocytopenia at a higher incidence and of longer duration than 25 similar patients who received azathioprine without SMZ/TMP.<sup>2</sup> Another report describes a similar severe leukopenia associated with use of trimethoprim together with azathioprine.<sup>3</sup> Of note, an observational study found that patients receiving azathioprine together with SMZ/TMP experienced no more hematologic toxicity than those receiving azathioprine together with another antibiotic.<sup>4</sup><br><br>The mechanism of this purported interaction is enhancement of 6-mercaptopurine (active moiety of azathioprine) bone marrow suppression by the antifolate actions of TMP/SMZ.<sup>2</sup> Case reports and data from cross-sectional and case-report studies support such an interaction, suggesting that SMZ/TMP can cause hematologic toxicity (independent of any combination with azathioprine).<sup>5,6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hulme B, Reeves DS, “Leucopenia Associated with Trimethoprim-Sulphamethoxazole after Renal Transplantation,” <i>Br Med J</i>, 1971, 3:610-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4936539\">[PubMed 4936539]</a></p>\n<p>2. Bradley PP, Warden GD, Maxwell JG, et al, “Neutropenia and Thrombocytopenia in Renal Allograft Recipients Treated with Trimethoprim-Sulfamethoxazole,” <i>Ann Intern Med</i>, 1980, 93:560-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7001973\">[PubMed 7001973]</a></p>\n<p>3. Bailey RR, “Leukopenia Due to a Trimethoprim-Azathioprine Interaction,” <i>N Z Med J</i>, 1984, 97:739. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6595562\">[PubMed 6595562]</a></p>\n<p>4. Hall CL, “Co-Trimoxazole and Azathioprine: A Safe Combination,” <i>Br Med J</i>, 1974, 4:15-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4609544\">[PubMed 4609544]</a></p>\n<p>5. Andres E, Noel E, Maloisel F, “Trimethoprim-Sulfamethoxazole-Induced Life-Threatening Agranulocytosis,” <i>Arch Intern Med</i>, 2003, 163(16):1975-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12963573\">[PubMed 12963573]</a></p>\n<p>6. van der Klauw MM, Goudsmit R, Halie MR, et al, “A Population-Based Case-Cohort Study of Drug-Associated Agranulocytosis,” <i>Arch Intern Med</i>, 1999, 159(4):369-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10030310\">[PubMed 10030310]</a></p>\n<p>7. van der Klauw MM, Wilson JH, Stricker BH, “Drug-Associated Agranulocytosis: 20 Years of Reporting in The Netherlands (1974-1994),” <i>Am J Hematol</i>, 1998, 57(3):206-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9495370\">[PubMed 9495370]</a></p>\n<p>8. Myers MW, Jick H, “Hospitalization for Serious Blood and Skin Disorders Following Co-Trimoxazole,” <i>Br J Clin Pharmacol</i>, 1997, 43(6):649-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9205827\">[PubMed 9205827]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4494":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Dasatinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dasatinib may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor the response to CYP3A4 substrates with a narrow therapeutic index when used together with dasatinib.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> Dasatinib prescribing information describes dasatinib as a weak, time-dependent inhibitor of CYP3A4 but recommends using caution when dasatinib is coadministered with a narrow therapeutic index CYP3A4 substrate.<sup>1</sup> A study in 54 healthy volunteers showed that a single dasatinib (100mg) dose given with simvastatin (a CYP3A4 substrate) resulted in a mean 37% increase in simvastatin maximum concentration and a 20% increase in simvastatin AUC.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sprycel (dasatinib). Princeton, NJ: Bristol-Myers Squibb, May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4495":"<p><b>Title</b> VinBLAStine / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of VinBLAStine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to vinblastine closely (particularly hematologic and neurologic status) when using vinblastine together with itraconazole.</p> \n<p><b>Discussion</b> One report describes severe myelosuppression and neurotoxicity in a patient in whom itraconazole was added to a chemotherapy regimen of vinblastine, doxorubicin, methotrexate, and prednisone.<sup>1</sup> Based on the nature of the toxicity and the patient's regimen, an interaction between itraconazole and vinblastine was considered primarily responsible for the observed toxicity. Several cell culture-/animal-based studies support this assertion, showing that itraconazole can significantly enhance cellular accumulation of vinblastine via a mechanism thought to involve itraconazole-mediated inhibition of P-glycoprotein, leading to a decrease in cellular efflux of vinblastine.<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bashir H, Motl S, Metzger ML, et al, “Itraconazole-Enhanced Chemotherapy Toxicity in a Patient with Hodgkin Lymphoma,” <i>J Pediatr Hematol Oncol</i>, 2006, 28(1):33-5.</p>\n<p>2. Iida N, Takara K, Ohmoto N, et al, “Reversal Effects of Antifungal Drugs on Multidrug Resistance in MDR1-Overexpressing HeLa Cells,” <i>Biol Pharm Bull</i>, 2001, 24(9):1032-6.</p>\n<p>3. Takara K, Tanigawara Y, Komada F, et al, “Cellular Pharmacokinetic Aspects of Reversal Effect of Itraconazole on P-glycoprotein-Mediated Resistance of Anticancer Drugs,” <i>Biol Pharm Bull</i>, 1999, 22(12):1355-9.</p>\n<p>4. Miyama T, Takanaga H, Matsuo H, et al, “P-glycoprotein-Mediated Transport of Itraconazole Across the Blood-Brain Barrier,” <i>Antimicrob Agents Chemother</i>, 1998, 42(7):1738-44.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4496":"<p><b>Title</b> Didanosine / Methadone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Methadone may decrease the serum concentration of Didanosine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If concurrent use of methadone with didanosine is necessary, enteric coated didanosine is preferred. Avoid using didanosine powder for solution with methadone. Increased monitoring of clinical response to didanosine (including viral load assessments, etc.) is necessary when using didanosine together with methadone.</p> \n<p><b>Discussion</b> Didanosine mean AUC and maximum serum concentrations (Cmax) were decreased by 29-57% and 41-66%, respectively, in 2 separate studies where single-doses of didanosine powder for solution (200 mg or 400 mg; n = 15-16) were administered to patients receiving stable methadone therapy (vs. historical controls, n = 10-68).<sup>1,2</sup> In comparison, a didanosine AUC and Cmax were an average of only 17% and 16% lower, respectively, in a single-dose study of enteric coated didanosine (400 mg) in patients on chronic methadone (vs. historical controls).<sup>3</sup><br><br>The mechanism of this interaction appears to involve both delayed absorption of and decreased bioavailability of didanosine by chronic methadone. The specific manner by which this occurs is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rainey PM, Friedland G, McCance-Katz EF, et al, “Interaction of Methadone with Didanosine and Stavudine,” <i>J Acquir Immune Defic Syndr</i>, 2000, 24(3):241-8.</p>\n<p>2. Prescribing information. Videx (didanosine). Princeton, NJ: Bristol-Myers Squibb Company, June 2009.</p>\n<p>3. Prescribing information. Videx EC (didanosine). Princeton, NJ: Bristol-Myers Squibb Company, June 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4497":"<p><b>Title</b> Midazolam / Erlotinib</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Erlotinib may decrease the serum concentration of Midazolam. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Erlotinib prescribing information states that concurrent administration of erlotinib and midazolam was associated with an average 24% reduction in midazolam AUC.<sup>1</sup> An in vitro study using recombinant CYP3A enzymes also showed that erlotinib enhanced both the CYP3A-mediated metabolism of midazolam and 1-hydroxymidazolam formation.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tarceva (erlotinib). Melville, NY: OSI Pharmaceuticals, Inc., 9/2008.</p>\n<p>2. Li J, Zhao M, He P, et al, “Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes,” <i>Clin Cancer Res</i>, 2007, 13(12):3731-7.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4498":"<p><b>Title</b> Erlotinib / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Erlotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Avoid concurrent administration of erlotinib with any proton pump inhibitor when possible. Due to the prolonged effect of proton pump inhibitors on gastric pH, separating administration of erlotinib and a proton pump inhibitor is unlikely to be an adequate means of avoiding an interaction.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> Erlotinib prescribing information states that the erlotinib maximum serum concentration (Cmax) and AUC were decreased by an average of 61% and 46%, respectively, when coadministered with the proton pump inhibitor (PPI) omeprazole.<sup>1</sup> In another study, in 14 patients who received erlotinib and esomeprazole (40 mg x 3 days) the erlotinib AUC and Cmax were 48% and 49% lower, respectively, than the AUC and Cmax of 14 patients who received erlotinib without esomeprazole.<sup>2</sup> The administration of 250 mL of an acidic beverage cola with erlotinib and esomeprazole increased the erlotinib AUC and Cmax 39% and 42%, respectively, but the AUC and Cmax were still 32% lower than those achieved when erlotinib was given alone.<sup>2</sup> A case report describes a patient in whom erlotinib minimum serum concentrations (Cmin) decreased by approximately 50% following initiation of intravenous pantoprazole 8 mg/hour.<sup>3</sup> Erlotinib Cmin returned to near baseline levels after conversion to oral pantoprazole (40 mg twice/day) despite the continued use of a relatively higher dose PPI. It is also important to note that the patient was using antacids (algeldrate/magnesium hydroxide 800 mg/400 mg 4 times/day, given 4 hours before or 2 hours after erlotinib administration) at determination of baseline erlotinib Cmin. While antacids are not expected to significantly alter erlotinib concentrations, whether such use at baseline impacted the evaluation of pantoprazole's effect is uncertain.<br><br>In contrast to studies suggesting an interaction with PPIs, the average erlotinib Cmin was not significantly different in users of acid suppression medications (PPIs or histamine-2 receptor antagonists) in a retrospective review of data from a randomized placebo-controlled trial conducted in patients with advanced or metastatic non-small cell lung cancer that did not prohibit use of acid suppressant medications (n=485 erlotinib recipients, 39% of whom were users of acid suppressants at any time during the trial).<sup>4</sup> Progression-free survival and overall survival were not significantly altered by use of acid suppressants. Diarrhea and infections were both more common among acid suppressant users, but this difference was apparent in both erlotinib and placebo recipients. The retrospective nature of this study, the uncontrolled use of acid suppressants (i.e., patients used various medications at various times and for variable durations), the lack of monitoring of adherence to reported medications, and the use of only Cmin (vs. Cmax or AUC) are several factors that make it difficult to reconcile these findings with those noted in the erlotinib prescribing information. These results do, however, raise important questions about the clinical significance of this purported interaction.<br><br>The suspected mechanism of this interaction is a decrease in erlotinib solubility in the upper gastrointestinal tract due to the PPI-mediated increase in gastric pH. Erlotinib solubility is known to be inversely related to gastric pH (i.e., solubility decreases with increasing pH).<sup>1</sup> Due to the prolonged effect of proton pump inhibitors on gastric pH, erlotinib prescribing information cautions that separating administration of erlotinib and a proton pump inhibitor is unlikely to be an adequate means of avoiding this interaction.<sup>1</sup> One additional possible mechanism specific to pantoprazole is inhibition of the ABCB1- and/or ABCG2-mediated transport of erlotinib.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tarceva</i> (erlotinib) [prescribing information]. Melville, NY: OSI Pharmaceuticals Inc; April 2014.</p>\n<p>2. van Leeuwen RW, Peric R, Hussaarts KG, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer [published online February 8, 2016]. <i>J Clin Oncol</i>. Doi: 10.1200/JCO.2015.65.2560. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26858332\">[PubMed 26858332]</a></p>\n<p>3. Ter Heine R, Fanggiday JC, Lankheet NA, et al. Erlotinib and pantoprazole: a relevant interaction or not? <i>Br J Clin Pharmacol</i>. 2010;70(6):908-911. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21175447\">[PubMed 21175447]</a></p>\n<p>4. Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. <i>Lung Cancer</i>. 2013;82(1):136-142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23910908\">[PubMed 23910908]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4499":"<p><b>Title</b> Erlotinib / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the serum concentration of Erlotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Avoid H2-antagonists in patients receiving erlotinib when possible. If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a study mentioned in erlotinib prescribing information, coadministration of erlotinib with ranitidine (300 mg) decreased erlotinib maximum serum concentration (Cmax) and AUC by 54% and 33%, respectively.<sup>1</sup> When erlotinib was administered with ranitidine (150 mg) twice daily, at least 10 hours after the evening ranitidine dose and 2 hours before the morning ranitidine dose, erlotinib Cmax and AUC were decreased by 17% and 15%, respectively.<br><br>In contrast to these data suggesting an interaction with histamine H2 receptor antagonists (H2RAs), erlotinib minimum serum concentrations (Cmin) were not significantly different in users of acid suppression medications (proton pump inhibitors or H2RAs) in a retrospective review of data from a randomized placebo-controlled trial conducted in patients with advanced or metastatic non-small cell lung cancer that did not prohibit use of acid suppressant medications (n=485 erlotinib recipients, 39% of whom were users of acid suppressants at any time during the trial).<sup>2</sup> Progression-free survival and overall survival were not significantly altered by use of acid suppressants. Diarrhea and infections were both more common among acid suppressant users, but this difference was apparent in both erlotinib and placebo recipients. The retrospective nature of this study, the uncontrolled use of acid suppressants (i.e., patients used various medications at various times and for variable durations), the lack of monitoring of adherence to reported medications, and the use of only Cmin (vs. Cmax or AUC) are several factors that make it difficult to reconcile these findings with those noted in the erlotinib prescribing information. These results do, however, raise important questions about the clinical significance of this purported interaction.<br><br>The suspected mechanism of this interaction is a decrease in erlotinib solubility in the upper gastrointestinal tract due to the ranitidine-mediated increase in gastric pH. Erlotinib solubility is known to be inversely related to gastric pH (i.e., solubility decreases with increasing pH).<sup>1</sup> In patients who require treatment with an H2RA such as ranitidine, erlotinib prescribing information recommends that erlotinib be dosed once daily, 10 hours after and at least 2 hours before H2RA dosing.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tarceva</i> (erlotinib) [prescribing information]. Melville, NY: OSI Pharmaceuticals, Inc.; April 2014.</p>\n<p>2. Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. <i>Lung Cancer</i>. 2013;82(1):136-142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23910908\">[PubMed 23910908]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}